<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:75.6pt;left:48.8pt;line-height:12.0pt"><span style="font-family:AdvHelv_B,serif;font-size:12.0pt">Feature Article</span></p>
<p style="top:93.4pt;left:48.8pt;line-height:15.9pt"><span style="font-family:AdvHelv_B,serif;font-size:15.9pt">Review Article</span></p>
<p style="top:135.4pt;left:48.8pt;line-height:20.4pt"><span style="font-family:AdvHelv_B,serif;font-size:20.4pt">Pharmacologic reduction of angiographic</span></p>
<p style="top:157.3pt;left:48.8pt;line-height:20.4pt"><span style="font-family:AdvHelv_B,serif;font-size:20.4pt">vasospasm in experimental subarachnoid</span></p>
<p style="top:179.3pt;left:48.8pt;line-height:20.4pt"><span style="font-family:AdvHelv_B,serif;font-size:20.4pt">hemorrhage: systematic review and meta-analysis</span></p>
<p style="top:215.9pt;left:48.8pt;line-height:12.0pt"><span style="font-family:AdvMelior,serif;font-size:12.0pt">Tommaso Zoerle</span><sup><span style="font-family:AdvMelior,serif;font-size:7.4pt">1</span></sup><span style="font-family:AdvMelior,serif;font-size:12.0pt">, Don C Ilodigwe</span><sup><span style="font-family:AdvMelior,serif;font-size:7.4pt">1</span></sup><span style="font-family:AdvMelior,serif;font-size:12.0pt">, Hoyee Wan</span><sup><span style="font-family:AdvMelior,serif;font-size:7.4pt">1</span></sup><span style="font-family:AdvMelior,serif;font-size:12.0pt">, Katarina Lakovic</span><sup><span style="font-family:AdvMelior,serif;font-size:7.4pt">2</span></sup><span style="font-family:AdvMelior,serif;font-size:12.0pt">, Mohammed Sabri</span><sup><span style="font-family:AdvMelior,serif;font-size:7.4pt">2</span></sup><span style="font-family:AdvMelior,serif;font-size:12.0pt">,</span></p>
<p style="top:227.9pt;left:48.8pt;line-height:12.0pt"><span style="font-family:AdvMelior,serif;font-size:12.0pt">Jinglu Ai</span><sup><span style="font-family:AdvMelior,serif;font-size:7.4pt">1</span></sup><sup><span style="font-family:AdvMelior,serif;font-size:12.0pt"> </span></sup><span style="font-family:AdvMelior,serif;font-size:12.0pt">and R Loch Macdonald</span><sup><span style="font-family:AdvMelior,serif;font-size:7.4pt">1,3</span></sup></p>
<p style="top:251.6pt;left:48.8pt;line-height:6.1pt"><span style="font-family:AdvMelior,serif;font-size:6.1pt">1</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">Division of Neurosurgery, St Michael&#x2019;s Hospital, Labatt Family Centre of Excellence in Brain Injury and</span></p>
<p style="top:264.3pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Trauma Research, Keenan Research Centre of the Li Ka Shing Knowledge Institute of St Michael&#x2019;s Hospital,</span></p>
<p style="top:276.3pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Ontario, Canada;</span><span style="font-family:AdvMelior,serif;font-size:6.1pt"> </span><sup><span style="font-family:AdvMelior,serif;font-size:6.1pt">2</span></sup><span style="font-family:AdvMelior,serif;font-size:10.0pt">Institute of Medical Science, University of Toronto, Ontario, Canada;</span><span style="font-family:AdvMelior,serif;font-size:6.1pt"> </span><sup><span style="font-family:AdvMelior,serif;font-size:6.1pt">3</span></sup><span style="font-family:AdvMelior,serif;font-size:10.0pt">Department of</span></p>
<p style="top:288.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Surgery, University of Toronto, Ontario, Canada</span></p>
<p style="top:326.1pt;left:60.8pt;line-height:10.0pt"><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">Animal models have been developed to simulate angiographic vasospasm secondary to subarachnoid</span></p>
<p style="top:336.6pt;left:60.8pt;line-height:10.0pt"><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">hemorrhage (SAH) and to test pharmacologic treatments. Our aim was to evaluate the effect of</span></p>
<p style="top:347.0pt;left:60.8pt;line-height:10.0pt"><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">pharmacologic treatments that have been tested in humans and in preclinical studies to determine if</span></p>
<p style="top:357.5pt;left:60.8pt;line-height:10.0pt"><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">animal models inform results reported in humans. A systematic review and meta-analysis of SAH</span></p>
<p style="top:367.9pt;left:60.8pt;line-height:10.0pt"><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">studies was performed. We investigated predictors of translation from animals to humans with</span></p>
<p style="top:378.4pt;left:60.8pt;line-height:10.0pt"><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">multivariate logistic regression. Pharmacologic reduction of vasospasm was effective in mice, rats,</span></p>
<p style="top:388.8pt;left:60.8pt;line-height:10.0pt"><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">rabbits, dogs, nonhuman primates (standard mean difference of</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xfffd;</span><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">1.74; 95% confidence interval</span></p>
<p style="top:399.3pt;left:60.8pt;line-height:10.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">2.04 to</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xfffd;</span><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">1.44) and humans. Animal studies were generally of poor methodologic quality and there</span></p>
<p style="top:409.7pt;left:60.8pt;line-height:10.0pt"><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">was evidence of publication bias. Subgroup analysis by drug and species showed that statins,</span></p>
<p style="top:420.2pt;left:60.8pt;line-height:10.0pt"><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">tissue plasminogen activator, erythropoietin, endothelin receptor antagonists, calcium channel</span></p>
<p style="top:430.7pt;left:60.8pt;line-height:10.0pt"><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">antagonists, fasudil, and tirilazad were effective whereas magnesium was not. Only evaluation</span></p>
<p style="top:441.2pt;left:60.8pt;line-height:10.0pt"><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">of vasospasm &gt; 3 days after SAH was independently associated with successful translation. We</span></p>
<p style="top:451.6pt;left:60.8pt;line-height:10.0pt"><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">conclude that reduction of vasospasm is effective in animals and humans and that evaluation</span></p>
<p style="top:462.1pt;left:60.8pt;line-height:10.0pt"><span style="font-family:AdvHelv_B,serif;font-size:10.0pt">of vasospasm &gt; 3 days after SAH may be preferable for preclinical models.</span></p>
<p style="top:472.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvHelv_O,serif;font-size:9.0pt">Journal of Cerebral Blood Flow &amp; Metabolism</span><span style="font-family:AdvHelv_R,serif;font-size:9.0pt"> (2012)</span><span style="font-family:AdvHelv_B,serif;font-size:9.0pt"> 32,</span><span style="font-family:AdvHelv_R,serif;font-size:9.0pt"> 1645&#x2013;1658; doi:10.1038/jcbfm.2012.57; published online</span></p>
<p style="top:482.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvHelv_R,serif;font-size:9.0pt">25 April 2012</span></p>
<p style="top:503.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvHelv_B,serif;font-size:9.0pt">Keywords:</span><span style="font-family:AdvHelv_R,serif;font-size:9.5pt"> animal model; pharmacologic reduction; subarachnoid hemorrhage; translation; vasospasm</span></p>
<p style="top:537.1pt;left:48.8pt;line-height:13.0pt"><span style="font-family:AdvHelv_B,serif;font-size:13.0pt">Introduction</span></p>
<p style="top:557.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Outcome from aneurysmal subarachnoid hemor-</span></p>
<p style="top:568.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">rhage</span></p>
<p style="top:568.4pt;left:82.4pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">(SAH)</span></p>
<p style="top:568.4pt;left:119.5pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">has</span></p>
<p style="top:568.4pt;left:143.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">improved.</span></p>
<p style="top:568.4pt;left:199.6pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Mortality</span></p>
<p style="top:568.4pt;left:250.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">declined</span></p>
<p style="top:579.3pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">0.4% per year, after adjustment for age, between</span></p>
<p style="top:590.3pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">1973 and 2002 (Nieuwkamp</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2009). The main</span></p>
<p style="top:601.3pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">changes in management that have occurred are</span></p>
<p style="top:612.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">improvements in intensive care, early securing of</span></p>
<p style="top:623.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">the ruptured aneurysm, and use of nimodipine.</span></p>
<p style="top:535.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Many other drugs have been tested in animal models</span></p>
<p style="top:546.6pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">but none has proven effective in high-quality clinical</span></p>
<p style="top:557.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">trials. Most of these studies tested drugs directed at</span></p>
<p style="top:568.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">reducing angiographic vasospasm. This was based on</span></p>
<p style="top:579.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">the hypothesis that since angiographic vasospasm is</span></p>
<p style="top:591.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">strongly correlated with cerebral infarction (Crowley</span></p>
<p style="top:602.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2011) and cerebral infarction is correlated with</span></p>
<p style="top:613.3pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">unfavorable clinical outcome on the Glasgow outcome</span></p>
<p style="top:624.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">scale (Fergusen and Macdonald, 2007) then reducing</span></p>
<p style="top:635.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">vasospasm should improve clinical outcome.</span></p>
<p style="top:646.4pt;left:312.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">There are many possible reasons for lack of transla-</span></p>
<p style="top:657.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">tion of reducing angiographic vasospasm in animal</span></p>
<p style="top:668.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">models to improving outcome in humans, including</span></p>
<p style="top:679.6pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">clinical trial design, whether the animal model</span></p>
<p style="top:690.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">reproduces the disease and methodological flaws</span></p>
<p style="top:701.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">in experimental studies (van der Worp</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2010).</span></p>
<p style="top:712.8pt;left:312.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Preclinical SAH studies for pharmaceutical reduc-</span></p>
<p style="top:723.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">tion of vasospasm differ in terms of animal used,</span></p>
<p style="top:716.5pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Received 14 November 2011; revised 12 February 2012; accepted</span></p>
<p style="top:725.4pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">28 February 2012; published online 25 April 2012</span></p>
<p style="top:650.7pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Correspondence: Dr RL Macdonald, Division of Neurosurgery, St</span></p>
<p style="top:659.7pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Michael&#x2019;s Hospital, University of Toronto, 30 Bond Street, Toronto,</span></p>
<p style="top:668.6pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Ontario M5B 1W8, Canada.</span></p>
<p style="top:677.6pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">E-mail: macdonaldlo@smh.ca</span></p>
<p style="top:687.5pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">This study was supported by grants from the Physicians Services</span></p>
<p style="top:697.5pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Incorporated Foundation and the Heart and Stroke Foundation of</span></p>
<p style="top:707.4pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Ontario to RL Macdonald.</span></p>
<p style="top:34.2pt;left:302.9pt;line-height:7.1pt"><span style="font-family:AdvNewsGothicB,serif;font-size:7.1pt">Journal of Cerebral Blood Flow &amp; Metabolism (2012) 32,</span><span style="font-family:AdvNewsGothicR,serif;font-size:7.1pt"> 1645&#x2013;1658</span></p>
<p style="top:43.1pt;left:302.9pt;line-height:7.1pt"><span style="font-family:AdvTA42,serif;font-size:7.1pt">&amp;</span><span style="font-family:AdvNewsGothicR,serif;font-size:7.0pt"> 2012 ISCBFM All rights reserved 0271-678X/12</span><span style="font-family:Advmac_NGothic,serif;font-size:6.8pt"> $</span><span style="font-family:AdvNewsGothicR,serif;font-size:6.8pt">32.00</span></p>
<p style="top:54.8pt;left:302.9pt;line-height:7.2pt"><span style="font-family:AdvNewsGothicR,serif;font-size:7.2pt">www.jcbfm.com</span></p>
<img style="position:absolute;transform:matrix(.374269,0,-0,.3851852,-38,-6.6653645)" src="data:image/png;base64,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">


<p style="top:66.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">induction of SAH, time course and severity of</span></p>
<p style="top:77.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">angiographic vasospasm (Megyesi</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2000; Titova</span></p>
<p style="top:88.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2009) as well in quality of design (i.e.,</span></p>
<p style="top:99.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">randomization, blinding). All these characteristics</span></p>
<p style="top:110.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">could impact the results of experimental treatment</span></p>
<p style="top:121.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">and perhaps the chance of translation, but to our</span></p>
<p style="top:132.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">knowledge there is no evidence that one model of</span></p>
<p style="top:142.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">SAH is better than any other for the purposes of</span></p>
<p style="top:153.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">predicting whether the findings in the animal study</span></p>
<p style="top:164.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">of a drug in relation to angiographic vasospasm are</span></p>
<p style="top:175.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">the</span></p>
<p style="top:175.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">same</span></p>
<p style="top:175.8pt;left:102.6pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">as</span></p>
<p style="top:175.8pt;left:120.1pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">what</span></p>
<p style="top:175.8pt;left:150.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">is</span></p>
<p style="top:175.8pt;left:166.7pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">found</span></p>
<p style="top:175.8pt;left:201.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">for</span></p>
<p style="top:175.8pt;left:222.7pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">its</span></p>
<p style="top:175.8pt;left:241.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">effects</span></p>
<p style="top:175.8pt;left:279.3pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">on</span></p>
<p style="top:186.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">angiographic vasospasm in human clinical trials. A</span></p>
<p style="top:197.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">meta-analysis of human clinical trials of drugs to</span></p>
<p style="top:208.7pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">decrease vasospasm showed that some, but ob-</span></p>
<p style="top:219.7pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">viously not all drugs tested did reduce vasospasm</span></p>
<p style="top:230.7pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">in randomized clinical trials (Etminan</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2011).</span></p>
<p style="top:241.6pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Thus, the primary hypothesis tested here was that</span></p>
<p style="top:252.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">some specific animal model or characteristic of one</span></p>
<p style="top:263.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">predicts the findings in clinical trials. The idea was</span></p>
<p style="top:274.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">that if, for example, one specific species or method of</span></p>
<p style="top:285.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">induction of SAH or some such characteristic of an</span></p>
<p style="top:296.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">animal model was more likely to be associated with</span></p>
<p style="top:307.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">successful translation to prevention of angiographic</span></p>
<p style="top:318.3pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">vasospasm in humans, then maybe that characteristic</span></p>
<p style="top:329.3pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">should be used for preclinical studies. The study of</span></p>
<p style="top:340.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Etminan</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> (2011) reported that in the clinical</span></p>
<p style="top:351.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">trials, angiographic vasospasm was reduced but there</span></p>
<p style="top:362.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">was no significant effect on clinical outcome. Thus,</span></p>
<p style="top:373.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">another hypothesis that could be tested would be</span></p>
<p style="top:384.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">what animal models or characteristics of them</span></p>
<p style="top:395.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">correlate with clinical outcome in humans. The</span></p>
<p style="top:406.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">present analysis focuses on angiographic vasospasm.</span></p>
<p style="top:434.6pt;left:48.8pt;line-height:13.0pt"><span style="font-family:AdvHelv_B,serif;font-size:13.0pt">Materials and methods</span></p>
<p style="top:455.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">We conducted this systematic review and meta-analysis</span></p>
<p style="top:466.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">according to the methods recommended for assessing health</span></p>
<p style="top:477.6pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">technologies and the Preferred Reporting Items for Systematic</span></p>
<p style="top:488.6pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Reviews and Meta-Analyses (PRISMA) guidelines (Higgins and</span></p>
<p style="top:499.5pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Green, 2008; Liberati</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">, 2009; Mignini and Khan, 2006;</span></p>
<p style="top:510.5pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Moher</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">, 2009). No language restrictions were used and two</span></p>
<p style="top:521.4pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">reviewers assessed each reference and determined study</span></p>
<p style="top:532.4pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">eligibility.</span></p>
<p style="top:563.1pt;left:48.8pt;line-height:9.5pt"><span style="font-family:AdvMelior,serif;font-size:9.5pt">Criteria for Included Animal Studies</span></p>
<p style="top:581.0pt;left:48.8pt;line-height:9.5pt"><span style="font-family:AdvMelior,serif;font-size:9.5pt">Type of studies</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">: We included preclinical studies</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> in vivo</span></p>
<p style="top:592.4pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">where SAH was simulated by endovascular puncture of a</span></p>
<p style="top:603.4pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cerebral artery, subarachnoid clot placement, or injection</span></p>
<p style="top:614.3pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">of blood, hemolyzed blood or other purported vasospastic</span></p>
<p style="top:625.2pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">substances into the subarachnoid space.</span></p>
<p style="top:647.5pt;left:48.8pt;line-height:9.5pt"><span style="font-family:AdvMelior,serif;font-size:9.5pt">Type of intervention</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">: We included studies of prophylactic</span></p>
<p style="top:658.9pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">treatment of angiographic vasospasm with any drug tested</span></p>
<p style="top:669.8pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">in both experimental and clinical trials for the same</span></p>
<p style="top:680.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">purpose. Intervention was defined as treatment for the</span></p>
<p style="top:691.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">purposes of this study if drug administration was started</span></p>
<p style="top:702.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">before or under the same anesthetic time as when the SAH</span></p>
<p style="top:713.6pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">was induced in the animal model or within 24 hours of the</span></p>
<p style="top:724.6pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">last injection of blood into the subarachnoid space. We did</span></p>
<p style="top:67.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">not include studies where drugs were administered to</span></p>
<p style="top:78.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">reverse established angiographic vasospasm. For selecting</span></p>
<p style="top:89.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">drugs, we considered a systematic review of drug treat-</span></p>
<p style="top:99.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">ments for humans with SAH and included all drugs tested</span></p>
<p style="top:110.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">in randomized, blinded clinical trials (Etminan</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">, 2011).</span></p>
<p style="top:132.7pt;left:302.9pt;line-height:9.5pt"><span style="font-family:AdvMelior,serif;font-size:9.5pt">Type of outcome</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">: The primary outcome was cerebral</span></p>
<p style="top:144.1pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm evaluated by catheter, CT (computed tomo-</span></p>
<p style="top:155.1pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">graphic), or magnetic resonance angiography or by histo-</span></p>
<p style="top:166.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">logical methods.</span></p>
<p style="top:196.4pt;left:302.9pt;line-height:9.5pt"><span style="font-family:AdvMelior,serif;font-size:9.5pt">Search Methods for Identification of Studies</span></p>
<p style="top:215.2pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Pubmed and Embase were searched from 1966 to Novem-</span></p>
<p style="top:226.1pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">ber 2010, using the following terms: (subarachnoid hemor-</span></p>
<p style="top:237.1pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">rhage) AND ((statin) OR (tissue plasminogen activator) OR</span></p>
<p style="top:248.1pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(ticlopidine) OR (erythropoietin) OR (clazosentan) OR</span></p>
<p style="top:259.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(nimodipine) OR (nicardipine) OR (fasudil) OR (tirilazad))</span></p>
<p style="top:269.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">AND (animal OR experimental). The same search was</span></p>
<p style="top:280.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">performed for magnesium, endothelin converting enzyme,</span></p>
<p style="top:291.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">and endothelin receptor antagonist. The reference lists of</span></p>
<p style="top:302.8pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">the papers were checked to identify other studies not</span></p>
<p style="top:313.8pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">found in the initial search.</span></p>
<p style="top:344.2pt;left:302.9pt;line-height:9.5pt"><span style="font-family:AdvMelior,serif;font-size:9.5pt">Data Collection</span></p>
<p style="top:363.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">For every included study, we extracted data on the species</span></p>
<p style="top:373.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">and sex of animals, method of induction of SAH, drug</span></p>
<p style="top:384.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">tested, timing and method of delivery of the drug, time and</span></p>
<p style="top:395.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">method for outcome assessment, randomization, blinding,</span></p>
<p style="top:406.8pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">sample size estimation, inclusion and exclusion criteria</span></p>
<p style="top:417.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">and physiological variables that were measured. Data on</span></p>
<p style="top:428.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">the number of animals and degree of vasospasm in</span></p>
<p style="top:439.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">treatment and control groups were extracted. If in the</span></p>
<p style="top:450.6pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">same study different doses or delivery way were used, data</span></p>
<p style="top:461.6pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">on the effect of the intervention were extracted for every</span></p>
<p style="top:472.6pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">group and the most effective regimen was used for the</span></p>
<p style="top:483.5pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">analysis, although for assessment of heterogeneity and</span></p>
<p style="top:494.4pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">publication bias, results for the best as well as all (114</span></p>
<p style="top:505.4pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">comparisons) are provided. If in the same study different</span></p>
<p style="top:516.4pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">drugs were tested, data on the effect of each drug were</span></p>
<p style="top:527.3pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">extracted and analyzed separately. Vasospasm was ex-</span></p>
<p style="top:538.3pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">pressed as the percent reduction in cerebral artery diameter</span></p>
<p style="top:549.3pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">from baseline (in the studies where angiographic evalua-</span></p>
<p style="top:560.2pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">tion was performed) or compared with control values (in</span></p>
<p style="top:571.1pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">the studies were histological evaluation was performed). If</span></p>
<p style="top:582.1pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">the degree of vasospasm was expressed as reduction in</span></p>
<p style="top:593.1pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">artery cross sectional area, the diameter was calculated</span></p>
<p style="top:604.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">using the formula: diameter = 2</span><span style="font-family:AdvP4C4E74,serif;font-size:9.0pt"> &#xfffd;</span><span style="font-family:AdvEls,serif;font-size:9.0pt"> O</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">(area/</span><span style="font-family:AdvPi2,serif;font-size:9.0pt">p</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">). If data were</span></p>
<p style="top:615.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">presented only in figures, then values were estimated using</span></p>
<p style="top:626.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">digital ruler software.</span></p>
<p style="top:636.9pt;left:311.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Methodologic quality of the animal studies was assessed</span></p>
<p style="top:647.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">by two reviewers by extracting data on study design,</span></p>
<p style="top:658.8pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">allocation</span></p>
<p style="top:658.8pt;left:351.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">concealment,</span></p>
<p style="top:658.8pt;left:413.2pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">blinding,</span></p>
<p style="top:658.8pt;left:458.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">number</span></p>
<p style="top:658.8pt;left:497.2pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">of</span></p>
<p style="top:658.8pt;left:512.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">animals</span></p>
<p style="top:669.8pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">randomized, age of animals, recording of physiologic</span></p>
<p style="top:680.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">variables, and inclusion of controls. We did not include</span></p>
<p style="top:691.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">funding source since this was not always reported, and we</span></p>
<p style="top:702.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">did not use a checklist and a score to assess study quality.</span></p>
<p style="top:713.6pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">This was because according to van der Worp</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> (2010),</span></p>
<p style="top:724.6pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">and other sources, use of these is controversial and it is not</span></p>
<p style="top:34.3pt;left:206.8pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicB,serif;font-size:6.9pt">Experimental vasospasm models</span></p>
<p style="top:43.3pt;left:256.6pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicR,serif;font-size:6.9pt">T Zoerle</span><span style="font-family:AdvNewsGothicI,serif;font-size:6.9pt"> et al</span></p>
<p style="top:58.4pt;left:12.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1646</span></p>
<p style="top:749.4pt;left:12.9pt;line-height:7.1pt"><span style="font-family:AdvNewsGothicB,serif;font-size:7.1pt">Journal of Cerebral Blood Flow &amp; Metabolism (2012) 32, 1645&#x2013;1658</span></p>


<p style="top:67.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">clear that any particular characteristics are better than any</span></p>
<p style="top:78.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">others. We also did not extract data on other variables</span></p>
<p style="top:89.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">reported in some other systematic reviews (such as the</span></p>
<p style="top:99.9pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">neuroprotective effect of anesthesia) because in most</span></p>
<p style="top:110.9pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">papers there were insufficient data provided.</span></p>
<p style="top:121.9pt;left:57.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">To assess the effect of each drug in human trials, the data</span></p>
<p style="top:132.8pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">were obtained from Etminan</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> (2011). The outcome</span></p>
<p style="top:143.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">measure was radiographic vasospasm, which was defined</span></p>
<p style="top:154.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">as a focal or generalized reduction of cerebral arterial</span></p>
<p style="top:165.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">caliber on catheter cerebral angiography, or increased</span></p>
<p style="top:176.6pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cerebral blood flow velocities on transcranial Doppler</span></p>
<p style="top:187.6pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">ultrasound. The included studies used various definitions</span></p>
<p style="top:198.6pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">of angiographic and transcranial Doppler vasospasm, so we</span></p>
<p style="top:209.5pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">used the definitions reported by the investigators of the</span></p>
<p style="top:220.4pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">original studies. If the investigators categorized angio-</span></p>
<p style="top:231.4pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">graphic vasospasm into no/mild, moderate, and severe</span></p>
<p style="top:242.4pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm, we used the number of patients that had</span></p>
<p style="top:253.3pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">moderate-to-severe vasospasm as an outcome event. Tran-</span></p>
<p style="top:264.3pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">scranial Doppler vasospasm was defined as flow velocity of</span></p>
<p style="top:275.3pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">at least 120 cm/s or peak flow velocity of &gt; 200 cm/s. If</span></p>
<p style="top:286.2pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">studies reported angiographic and transcranial Doppler</span></p>
<p style="top:297.2pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm, the data on angiographic vasospasm were used</span></p>
<p style="top:308.2pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(Etminan</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">, 2011).</span></p>
<p style="top:344.2pt;left:48.8pt;line-height:9.5pt"><span style="font-family:AdvMelior,serif;font-size:9.5pt">Statistical Analysis</span></p>
<p style="top:363.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">To test which species may reflect more accurately the effect</span></p>
<p style="top:373.9pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">of drug treatment on reducing vasospasm in humans, we</span></p>
<p style="top:384.9pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">analyzed the concordance between the drug effect in</span></p>
<p style="top:395.9pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">human and in the different animals. The drug effect in</span></p>
<p style="top:406.8pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">humans was defined as focal or generalized reduction in</span></p>
<p style="top:417.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cerebral</span></p>
<p style="top:417.7pt;left:89.1pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">artery</span></p>
<p style="top:417.7pt;left:120.3pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">diameter</span></p>
<p style="top:417.7pt;left:164.1pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">on</span></p>
<p style="top:417.7pt;left:182.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">catheter</span></p>
<p style="top:417.7pt;left:222.3pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">angiography,</span></p>
<p style="top:417.7pt;left:282.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">or</span></p>
<p style="top:428.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">increased cerebral blood flow velocities on transcranial</span></p>
<p style="top:439.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Doppler ultrasound, as reported previously (Etminan</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">,</span></p>
<p style="top:450.6pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">2011). If studies reported both catheter angiography and</span></p>
<p style="top:461.6pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Doppler ultrasound, angiography results were used, and</span></p>
<p style="top:472.6pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">the outcome event was number of patients with moderate</span></p>
<p style="top:483.5pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">or severe vasospasm. The effects were defined as con-</span></p>
<p style="top:494.4pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cordant if the drug showed evidence of positive effect in</span></p>
<p style="top:505.4pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">humans as well as in animals or no evidence of effect in</span></p>
<p style="top:516.4pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">humans as well as in animals. Drug effect was defined as</span></p>
<p style="top:527.3pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">discordant if the drug showed evidence of efficacy in</span></p>
<p style="top:538.3pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">animals but not in humans or vice versa.</span></p>
<p style="top:549.3pt;left:57.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">A random effect standardized meta-analysis was used to</span></p>
<p style="top:560.2pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">assess the effect of pharmacologic reduction of vasospasm</span></p>
<p style="top:571.1pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">in animal studies. Effect sizes were expressed as pooled</span></p>
<p style="top:582.1pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">standard mean difference. Subgroup analyses by drug and</span></p>
<p style="top:593.1pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">animal species were performed. We used meta-regression</span></p>
<p style="top:604.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">to analyze the source of heterogeneity, if any. Factors</span></p>
<p style="top:615.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">included in the meta-regression were species and sex of</span></p>
<p style="top:626.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">animals, method of induction of SAH, drug tested, route of</span></p>
<p style="top:636.9pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">drug delivery, treatment start time (before or after SAH),</span></p>
<p style="top:647.9pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">time and method of outcome assessment, randomization,</span></p>
<p style="top:658.8pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">blinding (for outcome assessment and whether animals</span></p>
<p style="top:669.8pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">belonged to treatment or control groups before surgery),</span></p>
<p style="top:680.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">monitoring of physiological variables (temperature, blood</span></p>
<p style="top:691.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">pressure, heart rate, oxygenation, intracranial pressure),</span></p>
<p style="top:702.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">and monitoring of CO</span><span style="font-family:AdvMelior,serif;font-size:5.5pt">2</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> (Table 1).</span></p>
<p style="top:713.6pt;left:57.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Publication bias was investigated using Begg&#x2019;s and</span></p>
<p style="top:724.6pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Egger&#x2019;s tests; Begg&#x2019;s funnel plots are shown. For human</span></p>
<p style="top:67.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">studies, effect sizes were expressed in pooled risk ratio</span></p>
<p style="top:78.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">estimates. To assess predictors of translation from animal</span></p>
<p style="top:89.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">to human, univariable and multivariable logistic regres-</span></p>
<p style="top:99.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">sions were used</span></p>
<p style="top:99.9pt;left:385.2pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">with the</span></p>
<p style="top:99.9pt;left:431.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">dependent</span></p>
<p style="top:99.9pt;left:482.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">variable being</span></p>
<p style="top:110.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">concordance/discordance of the drug. Variables entered</span></p>
<p style="top:121.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">in the regressions were the same as the variables used for</span></p>
<p style="top:132.8pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">meta-regression. Bonferroni correction was used for multi-</span></p>
<p style="top:143.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">ple comparisons.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> P</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> &lt; 0.05 was considered significant.</span></p>
<p style="top:179.2pt;left:302.9pt;line-height:13.0pt"><span style="font-family:AdvHelv_B,serif;font-size:13.0pt">Results</span></p>
<p style="top:199.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">A total of 453 studies were identified. Three hundred</span></p>
<p style="top:210.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">nineteen studies were excluded after review of the</span></p>
<p style="top:221.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">title and abstract showed the study was a review</span></p>
<p style="top:232.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">article, clinical studies with no single treatment,</span></p>
<p style="top:243.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">in-vitro</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> study or test of a treatment to reverse</span></p>
<p style="top:254.3pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">established angiographic vasospasm. An additional</span></p>
<p style="top:265.3pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">64 studies were excluded after reading the full text</span></p>
<p style="top:276.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">because they did not completely fulfill the inclusion</span></p>
<p style="top:287.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">criteria or they reported preliminary or incomplete</span></p>
<p style="top:298.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">data. Data from 70 papers were then extracted</span></p>
<p style="top:309.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">(Bilginer</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2009; Bulsara</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2006; Caner</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">,</span></p>
<p style="top:320.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">1996; Chang</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2010; Chen</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2009; Cheng</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">,</span></p>
<p style="top:331.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">2009; Chung and Lee, 1993; Cosentino</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1993;</span></p>
<p style="top:342.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Espinosa</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1984; Findlay</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1988, 1989, 1990;</span></p>
<p style="top:352.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Grasso</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2002; Gul</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2010; Hanggi</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2009;</span></p>
<p style="top:363.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Hariton</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1993; Hino</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1995; Itoh</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1993,</span></p>
<p style="top:374.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">1994; Josko</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2000; Kanamaru</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1990, 1991;</span></p>
<p style="top:385.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Kawada</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1999; Kawashima</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2000; Kim</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">,</span></p>
<p style="top:396.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">1996, 2000; Kita</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1998; Kwan</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1997, 2001,</span></p>
<p style="top:407.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">2006; Laslo</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2006; Lewis</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1988; Lin</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">,</span></p>
<p style="top:418.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">2007; Macdonald</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1998</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">b</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2004; Marbacher</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">,</span></p>
<p style="top:429.6pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">2008; Matsui and Asano, 1994; Matsumura</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">,</span></p>
<p style="top:440.6pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">1991; McGirt</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2002, 2006; Mesis</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2006;</span></p>
<p style="top:451.6pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Murphy</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2008; Nirei</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1993; Nosko</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">,</span></p>
<p style="top:462.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">1985; Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1999; Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1991;</span></p>
<p style="top:473.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Roux</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1997; Santhanam</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2005; Satoh</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">,</span></p>
<p style="top:484.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">1992; Seifert</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1989; Shigeno</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1995; Steinke</span></p>
<p style="top:495.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1989; Sugawara</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2008; Suzuki</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1998,</span></p>
<p style="top:506.3pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">1999; Takanashi</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2001</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">; Tang</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2008;</span></p>
<p style="top:517.3pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Turowski</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2007; Vollmer</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1989; Wanebo</span></p>
<p style="top:528.3pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1998; Wanebo</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1997; Wang</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2010;</span></p>
<p style="top:539.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Willette</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1994; Zabramski</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1986; Zimmer-</span></p>
<p style="top:550.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">mann</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1996; Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1989, 1996, 1998).</span></p>
<p style="top:561.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">In four papers, two drugs were tested, leading to a</span></p>
<p style="top:572.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">total of 74 comparisons for analysis (Cosentino</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">,</span></p>
<p style="top:583.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">1993; Hino</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1995; Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1996, 1998).</span></p>
<p style="top:594.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">There were 556 animals assigned to treatment groups</span></p>
<p style="top:605.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">and 664 to control groups.</span></p>
<p style="top:640.0pt;left:302.9pt;line-height:9.5pt"><span style="font-family:AdvMelior,serif;font-size:9.5pt">Characteristics of the Studies</span></p>
<p style="top:658.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Investigators used monkeys (Macaca species), dogs</span></p>
<p style="top:669.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">(mongrel</span></p>
<p style="top:669.0pt;left:351.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">or beagles), rabbits (Japanese</span></p>
<p style="top:669.0pt;left:506.5pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">or New</span></p>
<p style="top:679.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Zealand species), rats (Sprague Dawley or Wistar</span></p>
<p style="top:690.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">species) and mice (Table 1; Supplementary Table 1).</span></p>
<p style="top:701.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">The most used methods to simulate SAH were two</span></p>
<p style="top:712.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">injections of blood into the cisterna magna (dog,</span></p>
<p style="top:723.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">rabbit, and rat studies), a single injection of blood</span></p>
<p style="top:34.3pt;left:302.9pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicB,serif;font-size:6.9pt">Experimental vasospasm models</span></p>
<p style="top:43.3pt;left:302.9pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicR,serif;font-size:6.9pt">T Zoerle</span><span style="font-family:AdvNewsGothicI,serif;font-size:6.9pt"> et al</span></p>
<p style="top:58.4pt;left:563.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1647</span></p>
<p style="top:749.4pt;left:384.2pt;line-height:7.1pt"><span style="font-family:AdvNewsGothicB,serif;font-size:7.1pt">Journal of Cerebral Blood Flow &amp; Metabolism (2012) 32, 1645&#x2013;1658</span></p>


<p style="top:66.1pt;left:48.8pt;line-height:9.5pt"><span style="font-family:AdvNewsGothicB,serif;font-size:9.5pt">Table 1</span><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt"> Characteristics of animal studies</span></p>
<p style="top:86.0pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Characteristic</span></p>
<p style="top:86.0pt;left:126.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Number</span></p>
<p style="top:95.0pt;left:135.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(%)</span></p>
<p style="top:86.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">References</span></p>
<p style="top:116.1pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Species</span></p>
<p style="top:125.2pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Monkey</span></p>
<p style="top:125.2pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">16 (22)</span></p>
<p style="top:125.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Espinosa</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1984); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988, 1989, 1990); Hariton</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Hino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Kanamaru</span></p>
<p style="top:134.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1990, 1991); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Lewis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2004); Nosko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1985); Steinke</span></p>
<p style="top:143.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998, 1999)</span></p>
<p style="top:152.0pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Dog</span></p>
<p style="top:152.0pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">23 (31)</span></p>
<p style="top:152.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Chung and Lee (1993); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993, 1994); Kawashima</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:161.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2000); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kita</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Matsui and Asano (1994);</span></p>
<p style="top:169.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Nirei</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Roux</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997); Satoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1992);</span></p>
<p style="top:179.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Seifert</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Shigeno</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Willette</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Zabramski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:187.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1986); Zimmermann</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996)</span></p>
<p style="top:196.9pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Rabbit</span></p>
<p style="top:196.9pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">24 (32)</span></p>
<p style="top:196.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bilginer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Caner</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Grasso</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Kawada</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Kwan</span></p>
<p style="top:205.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 2001, 2006); Laslo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Lin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Marbacher</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006);</span></p>
<p style="top:214.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Murphy</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Santhanam</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2005); Tang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Vollmer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989);</span></p>
<p style="top:223.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 1998); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989, 1996, 1998)</span></p>
<p style="top:232.7pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Rat</span></p>
<p style="top:232.7pt;left:132.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">9 (12)</span></p>
<p style="top:232.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Cheng</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Josko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Sugawara</span></p>
<p style="top:241.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010)</span></p>
<p style="top:250.7pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Mouse</span></p>
<p style="top:250.7pt;left:132.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">2 (2)</span></p>
<p style="top:250.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010)</span></p>
<p style="top:268.6pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Sex</span></p>
<p style="top:277.5pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Male</span></p>
<p style="top:277.5pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">27 (36)</span></p>
<p style="top:277.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bilginer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Cheng</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Grasso</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Josko</span></p>
<p style="top:286.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 2001, 2006); Lin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002, 2006); Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006);</span></p>
<p style="top:295.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Murphy</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Nirei</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Santhanam</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2005); Sugawara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:304.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2008); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Tang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:313.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1997); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Willette</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996, 1998)</span></p>
<p style="top:322.4pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Female</span></p>
<p style="top:322.4pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">11 (14)</span></p>
<p style="top:322.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Espinosa</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1984); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988, 1989, 1990); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Kanamaru</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1990, 1991); Lewis</span></p>
<p style="top:331.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Nosko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1985); Steinke</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989)</span></p>
<p style="top:340.3pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Male/female</span></p>
<p style="top:340.3pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">36 (49)</span></p>
<p style="top:340.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Caner</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Chung and Lee (1993); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993);</span></p>
<p style="top:349.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Hariton</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Hino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993, 1994); Kawashima</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996,</span></p>
<p style="top:358.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">2000); Kita</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Laslo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a, b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">, 2004); Marbacher</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Matsui</span></p>
<p style="top:367.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">and Asano (1994); Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Roux</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997);</span></p>
<p style="top:376.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Satoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1992); Seifert</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Shigeno</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998, 1999); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:385.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Vollmer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Zabramski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1986); Zimmermann</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998)</span></p>
<p style="top:403.1pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Method of induction of SAH</span></p>
<p style="top:412.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Clot placement</span></p>
<p style="top:412.1pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">17 (23)</span></p>
<p style="top:412.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Espinosa</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1984); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988, 1989, 1990); Hariton</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Hino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Kanamaru</span></p>
<p style="top:421.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1990, 1991, 2000); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Lewis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2004); Nosko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1985);</span></p>
<p style="top:430.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Steinke</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998, 1999)</span></p>
<p style="top:438.9pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">2 Injections</span></p>
<p style="top:447.9pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">cisterna magna</span></p>
<p style="top:438.9pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">29 (39)</span></p>
<p style="top:438.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Chung and Lee (1993); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993, 1994); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000);</span></p>
<p style="top:447.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Kita</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Matsui and Asano (1994); Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Nirei</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:456.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1993); Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Roux</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997); Satoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1992); Seifert</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Shigeno</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995);</span></p>
<p style="top:465.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Willette</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Zimmermann</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:474.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2009); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996, 1998)</span></p>
<p style="top:483.8pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">One injection</span></p>
<p style="top:492.7pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">cisterna magna</span></p>
<p style="top:483.8pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">21 (28)</span></p>
<p style="top:483.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bilginer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Caner</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Grasso</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Kawada</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 2001,</span></p>
<p style="top:492.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">2006); Laslo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Lin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Marbacher</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Murphy</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008);</span></p>
<p style="top:501.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Santhanam</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2005); Vollmer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 1998); Zuccarello</span></p>
<p style="top:510.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Josko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007)</span></p>
<p style="top:519.6pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Endovascular</span></p>
<p style="top:528.6pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">perforation</span></p>
<p style="top:519.6pt;left:132.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">4 (5)</span></p>
<p style="top:519.6pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Cheng</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Sugawara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008)</span></p>
<p style="top:537.6pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Other</span><sup><span style="font-family:AdvMelior,serif;font-size:4.9pt">a</span></sup></p>
<p style="top:537.6pt;left:132.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">3 (4)</span></p>
<p style="top:537.6pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Tang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Zabramski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1986)</span></p>
<p style="top:555.5pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Severity of vasospasm in control group</span></p>
<p style="top:564.5pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Mild</span></p>
<p style="top:564.5pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">16 (22)</span></p>
<p style="top:564.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Chung and Lee (1993); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Hariton</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Josko</span></p>
<p style="top:573.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Laslo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Marbacher</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Murphy</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Sugawara</span></p>
<p style="top:582.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Tang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Zimmermann</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998)</span></p>
<p style="top:591.4pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Moderate</span></p>
<p style="top:591.4pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">55 (74)</span></p>
<p style="top:591.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Caner</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Cheng</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993);</span></p>
<p style="top:600.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Espinosa</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1984); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989, 1988); Grasso</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Hino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995);</span></p>
<p style="top:609.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Kanamaru</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1990, 1991); Kawada</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Kawashima</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:618.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1996, 2000); Kita</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 2001, 2006); Lewis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Lin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007);</span></p>
<p style="top:627.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">, 2004); Matsui and Asano (1994); Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002,</span></p>
<p style="top:636.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">2006); Nirei</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Nosko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1985); Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Roux</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997);</span></p>
<p style="top:645.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Santhanam</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2005); Satoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1992); Seifert</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Shigeno</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Steinke</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989);</span></p>
<p style="top:654.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998, 1999); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Vollmer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 1998; Wang</span></p>
<p style="top:663.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Willette</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989, 1996)</span></p>
<p style="top:672.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Severe</span></p>
<p style="top:672.1pt;left:132.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">3 (4)</span></p>
<p style="top:672.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bilginer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1990); Zabramski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1986)</span></p>
<p style="top:690.0pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Evaluation of vasospasm</span></p>
<p style="top:699.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Angiography</span></p>
<p style="top:699.0pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">52 (70)</span></p>
<p style="top:699.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Chung and Lee (1993); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Espinosa</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1984); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:708.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1988, 1989, 1990); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Hariton</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Hino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993, 1994);</span></p>
<p style="top:716.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Kanamaru</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1990, 1991); Kawada</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Kawashima</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996, 2000);</span></p>
<p style="top:34.3pt;left:206.8pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicB,serif;font-size:6.9pt">Experimental vasospasm models</span></p>
<p style="top:43.3pt;left:256.6pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicR,serif;font-size:6.9pt">T Zoerle</span><span style="font-family:AdvNewsGothicI,serif;font-size:6.9pt"> et al</span></p>
<p style="top:58.4pt;left:12.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1648</span></p>
<p style="top:749.4pt;left:12.9pt;line-height:7.1pt"><span style="font-family:AdvNewsGothicB,serif;font-size:7.1pt">Journal of Cerebral Blood Flow &amp; Metabolism (2012) 32, 1645&#x2013;1658</span></p>


<p style="top:64.3pt;left:48.8pt;line-height:8.5pt"><span style="font-family:AdvNewsGothicB,serif;font-size:8.5pt">Table 1</span></p>
<p style="top:64.3pt;left:83.1pt;line-height:8.5pt"><span style="font-family:AdvNewsGothicI,serif;font-size:8.5pt">Continued</span></p>
<p style="top:80.3pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Characteristic</span></p>
<p style="top:80.3pt;left:126.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Number</span></p>
<p style="top:89.3pt;left:135.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(%)</span></p>
<p style="top:80.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">References</span></p>
<p style="top:110.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Kita</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Laslo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Lewis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">, 2004); Marbacher</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:119.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2008); Matsui and Asano (1994); Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Murphy</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Nirei</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Nosko</span></p>
<p style="top:128.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1985); Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Roux</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997); Santhanam</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2005); Satoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1992); Seifert</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:137.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1989); Shigeno</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Steinke</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:146.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Tang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Willette</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Zabramski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1986);</span></p>
<p style="top:155.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Zimmermann</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989, 1996, 1998)</span></p>
<p style="top:164.2pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Histology</span></p>
<p style="top:164.2pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">22 (30)</span></p>
<p style="top:164.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bilginer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Caner</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Cheng</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Grasso</span></p>
<p style="top:173.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Josko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 2001, 2006); Lin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:182.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2002, 2006); Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Sugawara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">);</span></p>
<p style="top:191.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Vollmer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998, 1997); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010)</span></p>
<p style="top:209.1pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Day of evaluation of vasospasm</span></p>
<p style="top:218.0pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">3 days</span></p>
<p style="top:218.0pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">21 (28)</span></p>
<p style="top:218.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bilginer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Caner</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Grasso</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Josko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:227.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2000); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 2001, 2006); Lin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002, 2006); Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006);</span></p>
<p style="top:236.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Santhanam</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2005); Sugawara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Tang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Vollmer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:244.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1989); Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 1998); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989)</span></p>
<p style="top:253.9pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">&gt;3 days</span></p>
<p style="top:253.9pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">53 (72)</span></p>
<p style="top:253.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Chung and Lee (1993); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993);</span></p>
<p style="top:262.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Espinosa</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1984); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988, 1989, 1990); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Hariton</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Hino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:271.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1995); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993, 1994); Kanamaru</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1990, 1991); Kawada</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Kawashima</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000);</span></p>
<p style="top:280.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996, 2000); Kita</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Laslo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Lewis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span></p>
<p style="top:289.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">2004); Marbacher</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Matsui and Asano (1994); Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Murphy</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008);</span></p>
<p style="top:298.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Nirei</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Nosko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1985); Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Roux</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997); Satoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1992); Seifert</span></p>
<p style="top:307.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Shigeno</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Steinke</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998 1999); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">);</span></p>
<p style="top:316.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Willette</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Zabramski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1986); Zimmermann</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:325.6pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1996); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989, 1996)</span></p>
<p style="top:343.5pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Drug</span></p>
<p style="top:352.5pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Tirilazad</span></p>
<p style="top:352.5pt;left:132.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">8 (11)</span></p>
<p style="top:352.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Kanamaru</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1990, 1991); Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Matsui and Asano (1994); Steinke</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989);</span></p>
<p style="top:361.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Vollmer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989)</span></p>
<p style="top:370.5pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Calcium</span></p>
<p style="top:379.4pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">antagonist</span></p>
<p style="top:370.5pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">14 (19)</span></p>
<p style="top:370.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bilginer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Espinosa</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1984); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Kawashima</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000);</span></p>
<p style="top:379.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Laslo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Lewis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Marbacher</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Nosko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1985);</span></p>
<p style="top:388.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Tang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Zabramski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1986)</span></p>
<p style="top:397.3pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Erythropoietin</span></p>
<p style="top:397.3pt;left:132.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">4 (5)</span></p>
<p style="top:397.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Grasso</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Murphy</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Santhanam</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2005)</span></p>
<p style="top:406.4pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Statins</span></p>
<p style="top:406.4pt;left:132.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">7 (9)</span></p>
<p style="top:406.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Cheng</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002, 2006); Sugawara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:415.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2008); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010)</span></p>
<p style="top:424.3pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Endothelin</span></p>
<p style="top:433.2pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">antagonist/</span></p>
<p style="top:442.2pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">endothelin</span></p>
<p style="top:451.1pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">converting</span></p>
<p style="top:460.1pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">enzyme inhibitor</span></p>
<p style="top:424.3pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">26 (35)</span></p>
<p style="top:424.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Caner</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Hino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993, 1994); Josko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kita</span></p>
<p style="top:433.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 2001, 2006); Lin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:442.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1991); Nirei</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Roux</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997); Shigeno</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 1998); Willette</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:451.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1994); Zimmermann</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996, 1998)</span></p>
<p style="top:469.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Fasudil</span></p>
<p style="top:469.1pt;left:132.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">4 (5)</span></p>
<p style="top:469.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Satoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1992); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">)</span></p>
<p style="top:478.1pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Tissue</span></p>
<p style="top:487.0pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">plasminogen</span></p>
<p style="top:496.0pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">activator</span></p>
<p style="top:478.1pt;left:132.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">9 (12)</span></p>
<p style="top:478.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Chung and Lee (1993); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988, 1989, 1990); Hariton</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Kawada</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Ohkuma</span></p>
<p style="top:487.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Seifert</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998)</span></p>
<p style="top:504.9pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Magnesium</span></p>
<p style="top:504.9pt;left:132.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1 (1.5)</span></p>
<p style="top:504.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2004)</span></p>
<p style="top:513.9pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Other</span><sup><span style="font-family:AdvMelior,serif;font-size:4.9pt">b</span></sup></p>
<p style="top:513.9pt;left:132.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1 (1.5)</span></p>
<p style="top:513.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996)</span></p>
<p style="top:531.9pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Route of drug delivery</span></p>
<p style="top:540.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Intracranial</span></p>
<p style="top:540.8pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">30 (40)</span></p>
<p style="top:540.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Chung and Lee (1993); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988, 1989, 1990); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009);</span></p>
<p style="top:549.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Hariton</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Hino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Josko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kawada</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Kawashima</span></p>
<p style="top:558.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Kita</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Lewis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Marbacher</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:567.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1991); Nirei</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Santhanam</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2005); Seifert</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:576.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1998); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Willette</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998)</span></p>
<p style="top:585.7pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Systemic</span></p>
<p style="top:585.7pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">44 (60)</span></p>
<p style="top:585.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bilginer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Caner</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Cheng</span></p>
<p style="top:594.6pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Espinosa</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1984); Grasso</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Kanamaru</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:603.6pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1990, 1991); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 2001, 2006); Laslo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Lin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007);</span></p>
<p style="top:612.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">, 2004); Matsui and Asano (1994); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002, 2006); Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006);</span></p>
<p style="top:621.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Murphy</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Nosko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1985); Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Roux</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997); Satoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1992);</span></p>
<p style="top:630.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Shigeno</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Steinke</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Sugawara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Tang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008);</span></p>
<p style="top:639.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Vollmer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 1998); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Zabramski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1986); Zimmermann</span></p>
<p style="top:648.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989, 1996)</span></p>
<p style="top:666.3pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Pretreatment</span></p>
<p style="top:675.3pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Before induction</span></p>
<p style="top:684.3pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">of SAH</span></p>
<p style="top:675.3pt;left:132.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">7 (9)</span></p>
<p style="top:675.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Caner</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Cheng</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993, 1994); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002);</span></p>
<p style="top:684.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Vollmer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989)</span></p>
<p style="top:693.3pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">After induction</span></p>
<p style="top:702.2pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">of SAH</span></p>
<p style="top:693.3pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">67 (91)</span></p>
<p style="top:693.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bilginer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Chung and Lee (1993); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993);</span></p>
<p style="top:702.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Espinosa</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1984); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988, 1989, 1990); Grasso</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:711.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2009); Hariton</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Hino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Josko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kanamaru</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1990, 1991); Kawada</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:720.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1999); Kawashima</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996, 2000); Kita</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 2001, 2006);</span></p>
<p style="top:34.3pt;left:302.9pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicB,serif;font-size:6.9pt">Experimental vasospasm models</span></p>
<p style="top:43.3pt;left:302.9pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicR,serif;font-size:6.9pt">T Zoerle</span><span style="font-family:AdvNewsGothicI,serif;font-size:6.9pt"> et al</span></p>
<p style="top:58.4pt;left:563.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1649</span></p>
<p style="top:749.4pt;left:384.2pt;line-height:7.1pt"><span style="font-family:AdvNewsGothicB,serif;font-size:7.1pt">Journal of Cerebral Blood Flow &amp; Metabolism (2012) 32, 1645&#x2013;1658</span></p>


<p style="top:64.3pt;left:48.8pt;line-height:8.5pt"><span style="font-family:AdvNewsGothicB,serif;font-size:8.5pt">Table 1</span></p>
<p style="top:64.3pt;left:83.1pt;line-height:8.5pt"><span style="font-family:AdvNewsGothicI,serif;font-size:8.5pt">Continued</span></p>
<p style="top:80.3pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Characteristic</span></p>
<p style="top:80.3pt;left:126.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Number</span></p>
<p style="top:89.3pt;left:135.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(%)</span></p>
<p style="top:80.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">References</span></p>
<p style="top:110.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Laslo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Lewis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Lin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">, 2004); Marbacher</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:119.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2008); Matsui and Asano (1994); Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Murphy</span></p>
<p style="top:128.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Nirei</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Nosko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1985); Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Roux</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:137.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1997); Santhanam</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2005); Satoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1992); Seifert</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Shigeno</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Steinke</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:146.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1989); Sugawara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998, 1999); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Tang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008);</span></p>
<p style="top:155.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 1998); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Willette</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Zabramski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:164.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1986); Zimmermann</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998, 1989, 1996)</span></p>
<p style="top:182.2pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Blinding of outcome</span></p>
<p style="top:191.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">No</span></p>
<p style="top:191.1pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">29 (40)</span></p>
<p style="top:191.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993, 1994); Josko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kim</span></p>
<p style="top:200.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kita</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Laslo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Matsui and Asano (1994); Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); McGirt</span></p>
<p style="top:209.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Murphy</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Roux</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997);</span></p>
<p style="top:218.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Santhanam</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2005); Satoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1992); Seifert</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Shigeno</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">);</span></p>
<p style="top:227.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Tang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Vollmer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Willette</span></p>
<p style="top:236.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Zabramski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1986); Zimmermann</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989, 1998)</span></p>
<p style="top:244.9pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Yes</span></p>
<p style="top:244.9pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">45 (60)</span></p>
<p style="top:244.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bilginer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Caner</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Cheng</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Chung</span></p>
<p style="top:253.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">and Lee (1993); Espinosa</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1984); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988, 1989, 1990; Grasso</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:262.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2009); Hariton</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Hino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Kanamaru</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1990, 1991); Kawada</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999);</span></p>
<p style="top:271.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Kawashima</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 2001, 2006); Lewis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Lin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:280.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2007); Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">, 2004); Marbacher</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006);</span></p>
<p style="top:289.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Nirei</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Nosko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1985); Steinke</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Sugawara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998, 1999);</span></p>
<p style="top:298.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 1998); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Zuccarello</span></p>
<p style="top:307.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996)</span></p>
<p style="top:325.6pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Blinding to induction of SAH versus saline/sham surgery</span></p>
<p style="top:334.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">No</span></p>
<p style="top:334.6pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">59 (80)</span></p>
<p style="top:334.6pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Caner</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Cheng</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Chung</span></p>
<p style="top:343.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">and Lee (1993); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Espinosa</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1984); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989, 1990); Grasso</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:352.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2002); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993, 1994); Josko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kanamaru</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:361.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1990, 1991); Kawada</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kita</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001,</span></p>
<p style="top:370.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">2006); Laslo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Lewis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Lin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Marbacher</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Matsui and Asano</span></p>
<p style="top:379.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1994); Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002, 2006); Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Murphy</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Nirei</span></p>
<p style="top:388.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Roux</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997); Santhanam</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2005); Satoh</span></p>
<p style="top:397.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1992); Seifert</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Shigeno</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Sugawara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998, 1999);</span></p>
<p style="top:406.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Tang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Vollmer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998,</span></p>
<p style="top:415.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1997); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Willette</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Zabramski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1986); Zimmermann</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996);</span></p>
<p style="top:424.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989, 1996, 1998)</span></p>
<p style="top:433.2pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Yes</span></p>
<p style="top:433.2pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">15 (20)</span></p>
<p style="top:433.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bilginer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Hariton</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Hino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Kawashima</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000);</span></p>
<p style="top:442.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">, 2004); Nosko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1985); Steinke</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:451.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">)</span></p>
<p style="top:469.1pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Inclusion and exclusion criteria</span></p>
<p style="top:478.1pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">No</span></p>
<p style="top:478.1pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">65 (88)</span></p>
<p style="top:478.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bilginer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Espinosa</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1984);</span></p>
<p style="top:487.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988, 1989, 1990); Grasso</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Hariton</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:496.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1993); Hino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993, 1994); Josko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kanamaru</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1990, 1991); Kawada</span></p>
<p style="top:504.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Kawashima</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kita</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001,</span></p>
<p style="top:513.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">2006); Laslo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Lewis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Lin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">, 2004); Marbacher</span></p>
<p style="top:522.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Matsui and Asano (1994); Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006);</span></p>
<p style="top:531.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Murphy</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Nirei</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Nosko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1985); Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991);</span></p>
<p style="top:540.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Roux</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997); Santhanam</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2005); Satoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1992); Seifert</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Shigeno</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995);</span></p>
<p style="top:549.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Steinke</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998, 1999); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Tang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:558.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2007); Vollmer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Willette</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Zabramski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1986); Zimmermann</span></p>
<p style="top:567.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989, 1996, 1998)</span></p>
<p style="top:576.7pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Yes</span></p>
<p style="top:576.7pt;left:132.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">9 (12)</span></p>
<p style="top:576.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Caner</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Cheng</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Chung and Lee (1993); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997); McGirt</span></p>
<p style="top:585.7pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Sugawara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 1998)</span></p>
<p style="top:603.6pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Randomization</span></p>
<p style="top:612.5pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">No</span></p>
<p style="top:612.5pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">36 (49)</span></p>
<p style="top:612.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bilginer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Caner</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Cheng</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Chung and Lee (1993); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993);</span></p>
<p style="top:621.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Grasso</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993, 1994); Josko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kawada</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Kim</span></p>
<p style="top:630.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 2001, 2006); Lin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Matsui and Asano (1994); Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:639.5pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1991); Murphy</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Nirei</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Santhanam</span></p>
<p style="top:648.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2005); Satoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1992); Seifert</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Turowski</span></p>
<p style="top:657.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Willette</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Zabramski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1986); Zimmermann</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996);</span></p>
<p style="top:666.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998, 1989, 1996)</span></p>
<p style="top:675.3pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Yes</span></p>
<p style="top:675.3pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">38 (51)</span></p>
<p style="top:675.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Espinosa</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1984); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988, 1989,</span></p>
<p style="top:684.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1990); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Hariton</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Hino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Kanamaru</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1990, 1991); Kawashima</span></p>
<p style="top:693.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Kita</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Laslo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Lewis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:702.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">, 2004); Marbacher</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002, 2006); Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Nosko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1985);</span></p>
<p style="top:711.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Roux</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997); Shigeno</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Steinke</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Sugawara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999);</span></p>
<p style="top:720.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Tang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Vollmer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 1998); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010)</span></p>
<p style="top:34.3pt;left:206.8pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicB,serif;font-size:6.9pt">Experimental vasospasm models</span></p>
<p style="top:43.3pt;left:256.6pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicR,serif;font-size:6.9pt">T Zoerle</span><span style="font-family:AdvNewsGothicI,serif;font-size:6.9pt"> et al</span></p>
<p style="top:58.4pt;left:12.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1650</span></p>
<p style="top:749.4pt;left:12.9pt;line-height:7.1pt"><span style="font-family:AdvNewsGothicB,serif;font-size:7.1pt">Journal of Cerebral Blood Flow &amp; Metabolism (2012) 32, 1645&#x2013;1658</span></p>


<p style="top:362.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">into the cisterna magna (rabbit and rat studies) and</span></p>
<p style="top:373.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">craniotomy followed by clot placement around the</span></p>
<p style="top:384.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">cerebral arteries (all monkey and one dog studies). In</span></p>
<p style="top:395.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">the other studies, endovascular perforation (rat and</span></p>
<p style="top:406.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">mouse studies), prechiasmatic cistern blood injec-</span></p>
<p style="top:416.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">tion (one rat study) (Wang</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2010) or modified</span></p>
<p style="top:427.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">versions of cisterna magna injection (one rat (Tang</span></p>
<p style="top:438.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2008) and one dog study) (Zabramski</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 1986)</span></p>
<p style="top:449.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">were used. No studies injected hemolyzed blood or</span></p>
<p style="top:460.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">other substances into the subarachnoid space. In 48</span></p>
<p style="top:471.7pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">studies (52 experiments), vasospasm was assessed</span></p>
<p style="top:482.7pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">using catheter or CT angiography while 22 used</span></p>
<p style="top:493.7pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">histology. In 49 studies (53 experiments), vasospasm</span></p>
<p style="top:504.6pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">was evaluated &gt; 3 days after SAH and in 21 experi-</span></p>
<p style="top:515.6pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">ments evaluation was performed before or on day 3.</span></p>
<p style="top:526.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">The degree of vasospasm in the control group was</span></p>
<p style="top:537.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">mild (&lt;33%) in 16 experiments, moderate (33 to 66%)</span></p>
<p style="top:548.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">in 55 and severe (&gt;66%) in three.</span></p>
<p style="top:559.4pt;left:58.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Drugs tested included tirilazad, tissue plasmino-</span></p>
<p style="top:570.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">gen activator, calcium channel antagonists (nimodi-</span></p>
<p style="top:581.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">pine or nicardipine), erythropoietin, statins, fasudil,</span></p>
<p style="top:592.3pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">endothelin antagonists, or endothelin converting</span></p>
<p style="top:603.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">enzyme inhibitors, magnesium, and in one study,</span></p>
<p style="top:614.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">tissue plasminogen activator plus an endothelin</span></p>
<p style="top:625.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">antagonist. There were no experimental studies of</span></p>
<p style="top:636.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">ticlopidine. Drugs were administered intracranially</span></p>
<p style="top:647.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">in 30 experiments and systemically in 44 (intravenous,</span></p>
<p style="top:658.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">oral, or intraperitoneal). In seven cases, treatment was</span></p>
<p style="top:669.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">started before the induction of SAH (pretreatment).</span></p>
<p style="top:679.9pt;left:58.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Regarding the quality of the studies, none clearly</span></p>
<p style="top:690.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">reported</span></p>
<p style="top:690.9pt;left:96.0pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">a</span></p>
<p style="top:690.9pt;left:109.3pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">sample</span></p>
<p style="top:690.9pt;left:150.4pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">size</span></p>
<p style="top:690.9pt;left:176.5pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">calculation.</span></p>
<p style="top:690.9pt;left:238.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Only</span></p>
<p style="top:690.9pt;left:269.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">12%</span></p>
<p style="top:701.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">described inclusion and exclusion criteria, 51%</span></p>
<p style="top:712.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">used</span></p>
<p style="top:712.8pt;left:79.1pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">randomization,</span></p>
<p style="top:712.8pt;left:157.6pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">20%</span></p>
<p style="top:712.8pt;left:187.2pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">reported</span></p>
<p style="top:712.8pt;left:234.6pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">blinding</span></p>
<p style="top:712.8pt;left:282.0pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">of</span></p>
<p style="top:723.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">whether animals belonged to treatment or control</span></p>
<p style="top:362.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">group before surgery, and 60% reported blinding of</span></p>
<p style="top:373.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">assessment of outcome. Two or more of five physio-</span></p>
<p style="top:384.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">logical variables (heart rate, blood pressure, body</span></p>
<p style="top:395.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">temperature,</span></p>
<p style="top:395.0pt;left:371.0pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">intracranial</span></p>
<p style="top:395.0pt;left:434.1pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">pressure,</span></p>
<p style="top:395.0pt;left:485.7pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">oxygenation)</span></p>
<p style="top:406.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">were monitored in 80% of studies and blood or</span></p>
<p style="top:417.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">end-tidal CO</span><span style="font-family:AdvMelior,serif;font-size:6.1pt">2</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> was monitored in 78%.</span></p>
<p style="top:448.2pt;left:302.9pt;line-height:9.5pt"><span style="font-family:AdvMelior,serif;font-size:9.5pt">Overall Treatment Effect</span></p>
<p style="top:466.3pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">The pooled effect size expressed as standard mean</span></p>
<p style="top:477.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">difference showed that pharmacologic treatments</span></p>
<p style="top:488.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">significantly reduced cerebral vasospasm in the</span></p>
<p style="top:499.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">experimental studies (standard mean difference of</span></p>
<p style="top:510.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">1.74;. 95% CI (confidence interval)</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">2.04 to</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">1.44;</span></p>
<p style="top:521.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Figure 1). Substantial and significant heterogeneity</span></p>
<p style="top:532.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">was</span></p>
<p style="top:532.0pt;left:329.7pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">detected</span></p>
<p style="top:532.0pt;left:377.6pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">(heterogeneity</span></p>
<p style="top:532.0pt;left:452.0pt;line-height:10.0pt"><span style="font-family:AdvPi2,serif;font-size:10.0pt">w</span><sup><span style="font-family:AdvMelior,serif;font-size:6.1pt">2</span></sup></p>
<p style="top:532.0pt;left:469.6pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">statistic = 340.60</span></p>
<p style="top:543.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">(degrees of freedom = 73),</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> P</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> = 0.0001). In univariate</span></p>
<p style="top:553.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">meta-regression including all characteristics reported</span></p>
<p style="top:564.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">in Table 1, only the use of calcium antagonists</span></p>
<p style="top:575.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">(nicardipine or nimodipine) showed a significant</span></p>
<p style="top:586.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">association with the pooled effect size. Blinding</span></p>
<p style="top:597.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">induction of SAH revealed a marginal association</span></p>
<p style="top:608.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">(</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">P</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">= 0.052). In the multivariate meta-regression includ-</span></p>
<p style="top:619.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">ing study factors with</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> P</span><span style="font-family:AdvEls,serif;font-size:10.0pt">r</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">0.15, treatment with calcium</span></p>
<p style="top:630.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">antagonists remained significantly associated with the</span></p>
<p style="top:641.6pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">pooled effect size (Supplementary Table 1).</span></p>
<p style="top:672.9pt;left:302.9pt;line-height:9.5pt"><span style="font-family:AdvMelior,serif;font-size:9.5pt">Subgroup Analysis by Drug</span></p>
<p style="top:690.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Subgroup analysis by drug showed that every drug</span></p>
<p style="top:701.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">except magnesium was effective for reducing vasos-</span></p>
<p style="top:712.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">pasm. Heterogeneity was detected for every subgroup</span></p>
<p style="top:723.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">except for fasudil (Figure 2). Meta-regression was</span></p>
<p style="top:64.3pt;left:48.8pt;line-height:8.5pt"><span style="font-family:AdvNewsGothicB,serif;font-size:8.5pt">Table 1</span></p>
<p style="top:64.3pt;left:83.1pt;line-height:8.5pt"><span style="font-family:AdvNewsGothicI,serif;font-size:8.5pt">Continued</span></p>
<p style="top:80.3pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Characteristic</span></p>
<p style="top:80.3pt;left:126.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Number</span></p>
<p style="top:89.3pt;left:135.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(%)</span></p>
<p style="top:80.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">References</span></p>
<p style="top:113.4pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Monitoring of physiologic variables</span></p>
<p style="top:122.4pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">No</span></p>
<p style="top:122.4pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">15 (20)</span></p>
<p style="top:122.4pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Itoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993, 1994); Josko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000);</span></p>
<p style="top:131.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Kawada</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kita</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998); Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006);</span></p>
<p style="top:140.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999); Seifert</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007)</span></p>
<p style="top:149.3pt;left:56.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Yes</span></p>
<p style="top:149.3pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">59 (80)</span></p>
<p style="top:149.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bilginer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Caner</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Chen</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Cheng</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Chung</span></p>
<p style="top:158.3pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">and Lee (1993); Espinosa</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1984); Findlay</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988, 1989, 1990); Grasso</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:167.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2009); Hariton</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Hino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Kanamaru</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1990, 1991); Kawashima</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kim</span></p>
<p style="top:176.2pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Kwan</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 2001, 2006); Laslo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Lewis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1988); Lin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007);</span></p>
<p style="top:185.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Macdonald</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">, 2004); Marbacher</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Matsui and Asano (1994); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2002);</span></p>
<p style="top:194.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Murphy</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Nirei</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Nosko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1985); Pasqualin</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Roux</span></p>
<p style="top:203.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997); Santhanam</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2005); Satoh</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1992); Shigeno</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1995); Steinke</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989); Sugawara</span></p>
<p style="top:212.1pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Suzuki</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1998, 1999); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">,</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> b</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Tang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2008); Vollmer</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989);</span></p>
<p style="top:221.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Wanebo</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1997, 1998); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Willette</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1994); Zabramski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1986); Zimmermann</span></p>
<p style="top:230.0pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1996); Zuccarello</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1989, 1996, 1998)</span></p>
<p style="top:247.9pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Monitoring CO</span><span style="font-family:AdvMelior,serif;font-size:4.9pt">2</span></p>
<p style="top:256.9pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">No</span></p>
<p style="top:256.9pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">16 (22)</span></p>
<p style="top:256.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Bulsara</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Cosentino</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1993); Kim</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Matsumura</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1991); Ohkuma</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (1999)</span></p>
<p style="top:265.9pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Yes</span></p>
<p style="top:265.9pt;left:127.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">58 (78)</span></p>
<p style="top:265.9pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Chang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Cheng</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Gul</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2010); Hanggi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2009); Josko</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2000); Kawada</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:274.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(1999); McGirt</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Mesis</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2006); Takanashi</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2001</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">a</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">); Turowski</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> (2007); Wang</span><span style="font-family:AdvMelior,serif;font-size:8.0pt"> et al</span></p>
<p style="top:283.8pt;left:162.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2010)</span></p>
<p style="top:304.5pt;left:48.8pt;line-height:7.5pt"><span style="font-family:AdvNewsGothicR,serif;font-size:7.5pt">SAH, subarachnoid hemorrhage.</span></p>
<p style="top:312.3pt;left:48.8pt;line-height:6.1pt"><span style="font-family:AdvMelior,serif;font-size:6.1pt">a</span><span style="font-family:AdvNewsGothicR,serif;font-size:7.5pt">Modified cisterna magna injection and prechiasmatic cistern injection.</span></p>
<p style="top:323.3pt;left:48.8pt;line-height:6.1pt"><span style="font-family:AdvMelior,serif;font-size:6.1pt">b</span><span style="font-family:AdvNewsGothicR,serif;font-size:7.5pt">Tissue plasminogen activator plus endothelin antagonist.</span></p>
<p style="top:34.3pt;left:302.9pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicB,serif;font-size:6.9pt">Experimental vasospasm models</span></p>
<p style="top:43.3pt;left:302.9pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicR,serif;font-size:6.9pt">T Zoerle</span><span style="font-family:AdvNewsGothicI,serif;font-size:6.9pt"> et al</span></p>
<p style="top:58.4pt;left:563.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1651</span></p>
<p style="top:749.4pt;left:384.2pt;line-height:7.1pt"><span style="font-family:AdvNewsGothicB,serif;font-size:7.1pt">Journal of Cerebral Blood Flow &amp; Metabolism (2012) 32, 1645&#x2013;1658</span></p>


<p style="top:603.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">conducted for drug type versus variables signifi-</span></p>
<p style="top:614.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">cantly (</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">P</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> &lt; 0.05) associated in univariate analysis.</span></p>
<p style="top:625.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">This showed that the effect of erythropoietin and</span></p>
<p style="top:636.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">statins were associated with the method of induction</span></p>
<p style="top:647.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">of SAH, while calcium antagonist effect was related</span></p>
<p style="top:658.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">to the use of monkeys and mice (Table 2). This means</span></p>
<p style="top:669.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">that the effect of erythropoietin and statins are</span></p>
<p style="top:679.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">different (higher for statins, smaller for erythropoie-</span></p>
<p style="top:690.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">tin) in studies where cisterna magna double injection</span></p>
<p style="top:701.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">model was used compared with studies where cisterna</span></p>
<p style="top:712.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">magna single injection was used and that effect of</span></p>
<p style="top:723.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">calcium channel antagonists were different in studies</span></p>
<p style="top:460.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">where monkeys (smaller effect) or mice (higher effect)</span></p>
<p style="top:471.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">where used compared with the other studies.</span></p>
<p style="top:503.0pt;left:302.9pt;line-height:9.5pt"><span style="font-family:AdvMelior,serif;font-size:9.5pt">Subgroup Analysis by Species</span></p>
<p style="top:521.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Subgroup analysis by species showed that pharmaco-</span></p>
<p style="top:532.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">logic treatment was effective in all species (Figure 2).</span></p>
<p style="top:543.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Again, heterogeneity was detected and meta-regression</span></p>
<p style="top:553.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">showed that the pooled effect in rats was associated</span></p>
<p style="top:564.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">with the method of induction of SAH, in dogs with</span></p>
<p style="top:575.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">use of tissue plasminogen activator, and in monkeys</span></p>
<p style="top:586.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">with tirilazad and severity of vasospasm (Table 2).</span></p>
<p style="top:597.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">The heterogeneity means that in rats, treatment effect</span></p>
<p style="top:608.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">was higher when cisterna magna models were used,</span></p>
<p style="top:619.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">that in dogs, tissue plasminogen activator was more</span></p>
<p style="top:630.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">effective than other drugs, and that in monkeys,</span></p>
<p style="top:641.6pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">tirilizad was more effective compared with other</span></p>
<p style="top:652.6pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">drugs and that treatment effect was higher when</span></p>
<p style="top:663.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">drugs where tested against severe vasospasm.</span></p>
<p style="top:694.8pt;left:302.9pt;line-height:9.5pt"><span style="font-family:AdvMelior,serif;font-size:9.5pt">Publication Bias</span></p>
<p style="top:712.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Both the Begg&#x2019;s (</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">z</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">-score continuity corrected 6.68,</span></p>
<p style="top:723.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">P</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> = 0.000) and Egger&#x2019;s test (bias coefficient</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">4.83;</span></p>
<img style="position:absolute;transform:matrix(.6399973,0,-0,.6395055,-18.481995,-86.257389)" src="data:image/jpeg;base64,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">
<p style="top:542.1pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicB,serif;font-size:9.0pt">Figure 1</span><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt"> Effect size of 74 animal studies of pharmacologic</span></p>
<p style="top:552.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt">reduction of vasospasm included in meta-analysis. Gray band</span></p>
<p style="top:562.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt">represents overall effect with 95% confidence intervals (</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">*</span><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt"> and</span></p>
<p style="top:571.9pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">**</span><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt"> are effect of different drugs in the same publication).</span></p>
<img style="position:absolute;transform:matrix(.6399973,0,-0,.63950058,320.2473,-26.777344)" src="data:image/jpeg;base64,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">
<p style="top:383.8pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicB,serif;font-size:9.0pt">Figure 2</span><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt"> Effect size of the 74 included studies grouped by</span></p>
<p style="top:393.8pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt">animal and drug. Gray band represents overall effect with 95%</span></p>
<p style="top:403.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt">confidence interval. The size of the circle reflects the number of</span></p>
<p style="top:413.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt">animals included in the different subgroups (ET antagonist:</span></p>
<p style="top:423.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt">endothelin</span></p>
<p style="top:423.7pt;left:350.9pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt">antagonist</span></p>
<p style="top:423.7pt;left:398.2pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt">and</span></p>
<p style="top:423.7pt;left:420.7pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt">endothelin</span></p>
<p style="top:423.7pt;left:468.7pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt">converting</span></p>
<p style="top:423.7pt;left:516.1pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt">enzyme</span></p>
<p style="top:433.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt">inhibitor, MgSO</span><span style="font-family:AdvNewsGothicR,serif;font-size:5.5pt">4</span><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt">: magnesium).</span></p>
<p style="top:34.3pt;left:206.8pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicB,serif;font-size:6.9pt">Experimental vasospasm models</span></p>
<p style="top:43.3pt;left:256.6pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicR,serif;font-size:6.9pt">T Zoerle</span><span style="font-family:AdvNewsGothicI,serif;font-size:6.9pt"> et al</span></p>
<p style="top:58.4pt;left:12.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1652</span></p>
<p style="top:749.4pt;left:12.9pt;line-height:7.1pt"><span style="font-family:AdvNewsGothicB,serif;font-size:7.1pt">Journal of Cerebral Blood Flow &amp; Metabolism (2012) 32, 1645&#x2013;1658</span></p>


<p style="top:482.7pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">95% CI</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">5.96 to</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">3.69;</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> P</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> = 0.000) of heterogeneity in</span></p>
<p style="top:493.6pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">the 74 most effective doses in the pooled studies</span></p>
<p style="top:504.6pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">returned</span></p>
<p style="top:504.6pt;left:96.7pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">strong</span></p>
<p style="top:504.6pt;left:133.5pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">evidence</span></p>
<p style="top:504.6pt;left:183.1pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">of</span></p>
<p style="top:504.6pt;left:200.5pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">heterogeneity.</span></p>
<p style="top:504.6pt;left:273.1pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">The</span></p>
<p style="top:515.6pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">results were similar when including all 114 dose</span></p>
<p style="top:526.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">regimens tested (Begg&#x2019;s</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> z</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">-score continuity corrected</span></p>
<p style="top:537.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">8.18,</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> P</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> = 0.000 and Egger&#x2019;s test bias coefficient</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">4.79;</span></p>
<p style="top:548.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">95% CI</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">5.75 to</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">3.84;</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> P</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> = 0.000). Furthermore,</span></p>
<p style="top:559.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Begg&#x2019;s funnel plot showing asymmetric orientation of</span></p>
<p style="top:570.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">the data points for both analyses (Figure 3).</span></p>
<p style="top:607.7pt;left:48.8pt;line-height:9.5pt"><span style="font-family:AdvMelior,serif;font-size:9.5pt">Treatment Effect of Different Drugs in Different Species</span></p>
<p style="top:618.1pt;left:48.8pt;line-height:9.5pt"><span style="font-family:AdvMelior,serif;font-size:9.5pt">and Translation</span></p>
<p style="top:636.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Considering separately the effect of the different</span></p>
<p style="top:647.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">drugs in the different species, it is interesting to note</span></p>
<p style="top:658.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">that calcium antagonists and endothelin antagonists</span></p>
<p style="top:669.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">showed no significant effect in monkeys, statins had</span></p>
<p style="top:679.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">no significant effect in dogs, and endothelin antago-</span></p>
<p style="top:690.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">nists had no significant effects in rats (Table 3).</span></p>
<p style="top:701.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Therefore, the argument that all drugs are effective in</span></p>
<p style="top:712.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">animal models is not correct. We next considered data</span></p>
<p style="top:723.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">in a systematic review of the effect of pharmaceutical</span></p>
<p style="top:427.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">reduction of radiographic vasospasm with different</span></p>
<p style="top:438.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">drugs in human clinical trials (Etminan</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2011).</span></p>
<p style="top:449.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Drug effects were classified as concordant or dis-</span></p>
<p style="top:460.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">cordant based simply on whether or not the study</span></p>
<p style="top:471.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">or group of studies demonstrated a statistically</span></p>
<p style="top:482.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">significant effect on vasospasm. If, for example, the</span></p>
<p style="top:493.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">drug reduced vasospasm in dogs and in humans, or</span></p>
<p style="top:504.6pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">did not do so in either, then it was concordant. Any</span></p>
<p style="top:515.6pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">other result was discordant. Fasudil, endothelin</span></p>
<p style="top:526.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">antagonists (clazosentan), and tissue plasminogen</span></p>
<p style="top:537.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">activator showed a beneficial effect on angiographic</span></p>
<p style="top:548.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">vasospasm in humans while calcium antagonists</span></p>
<p style="top:559.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">(nimodipine and nicardipine), erythropoietin, statins,</span></p>
<p style="top:570.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">and tirilizad showed no significant effect (Table 3).</span></p>
<p style="top:581.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Since no data were available on the effects of</span></p>
<p style="top:592.3pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">magnesium and tissue plasminogen activator plus</span></p>
<p style="top:603.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">endothelin</span></p>
<p style="top:603.2pt;left:360.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">antagonists,</span></p>
<p style="top:603.2pt;left:423.4pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">experiments</span></p>
<p style="top:603.2pt;left:488.0pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">using</span></p>
<p style="top:614.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">treatments were excluded from further analysis.</span><sup><span style="font-family:AdvMelior,serif;font-size:10.0pt">these</span></sup></p>
<p style="top:625.2pt;left:312.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Two of the four drugs (50%) tested in monkeys</span></p>
<p style="top:636.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">presented results concordant with clinical trials</span></p>
<p style="top:647.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">(calcium channel antagonists had no significant</span></p>
<p style="top:658.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">effects in either, tissue plasminogen activator was</span></p>
<p style="top:669.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">significantly effective in both). In dogs, four (statins</span></p>
<p style="top:679.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">had no significant effects whereas fasudil, tissue</span></p>
<p style="top:690.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">plasminogen activator, and endothelin antagonists/</span></p>
<p style="top:701.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">endothelin converting enzyme inhibitors had sig-</span></p>
<p style="top:712.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">nificant effects) of six drugs (67%) were concordant</span></p>
<p style="top:723.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">and in rabbits, two (tissue plasminogen activator and</span></p>
<p style="top:66.1pt;left:48.8pt;line-height:9.5pt"><span style="font-family:AdvNewsGothicB,serif;font-size:9.5pt">Table 2</span><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt"> Subgroup analysis by drug and species</span></p>
<p style="top:86.0pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Drug</span></p>
<p style="top:86.0pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Variable</span></p>
<p style="top:86.0pt;left:205.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Regression</span></p>
<p style="top:95.0pt;left:205.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">coefficient</span></p>
<p style="top:103.9pt;left:193.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(95% confidence</span></p>
<p style="top:112.9pt;left:209.3pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">interval)</span></p>
<p style="top:86.0pt;left:262.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">P</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">-value</span></p>
<p style="top:134.1pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Erythropoietin</span></p>
<p style="top:134.1pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Single versus</span></p>
<p style="top:143.1pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">double</span></p>
<p style="top:152.0pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Cisterna magna</span></p>
<p style="top:161.0pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">injection</span></p>
<p style="top:152.0pt;left:217.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">5.31</span></p>
<p style="top:161.0pt;left:200.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(2.50 to 8.13)</span></p>
<p style="top:152.0pt;left:266.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.000</span></p>
<p style="top:179.0pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Calcium channel</span></p>
<p style="top:187.9pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">antagonists</span></p>
<p style="top:179.0pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Monkeys</span></p>
<p style="top:179.0pt;left:217.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.78</span></p>
<p style="top:187.9pt;left:200.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(0.14 to 1.42)</span></p>
<p style="top:179.0pt;left:266.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.017</span></p>
<p style="top:196.9pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Mice</span></p>
<p style="top:196.9pt;left:213.9pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.78</span></p>
<p style="top:205.8pt;left:194.3pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">4.26 to</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.29)</span></p>
<p style="top:196.9pt;left:266.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.000</span></p>
<p style="top:223.7pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Statin</span></p>
<p style="top:223.7pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Single versus</span></p>
<p style="top:232.7pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">double</span></p>
<p style="top:241.7pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Cisterna magna</span></p>
<p style="top:250.7pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">injection</span></p>
<p style="top:241.7pt;left:217.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">4.38</span></p>
<p style="top:250.7pt;left:194.3pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.55 to</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">7.21)</span></p>
<p style="top:241.7pt;left:266.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.002</span></p>
<p style="top:280.8pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Species</span></p>
<p style="top:280.8pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Variable</span></p>
<p style="top:280.8pt;left:205.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Regression</span></p>
<p style="top:289.8pt;left:205.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">coefficient</span></p>
<p style="top:298.7pt;left:193.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(95% confidence</span></p>
<p style="top:307.7pt;left:209.3pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">interval)</span></p>
<p style="top:280.8pt;left:262.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">P</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">-value</span></p>
<p style="top:328.9pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Dog</span></p>
<p style="top:328.9pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Tissue</span></p>
<p style="top:337.8pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">plasminogen</span></p>
<p style="top:346.8pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Activator</span></p>
<p style="top:346.8pt;left:213.9pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.06</span></p>
<p style="top:355.8pt;left:194.3pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">3.66 to</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.46)</span></p>
<p style="top:346.8pt;left:266.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.012</span></p>
<p style="top:373.7pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Monkey</span></p>
<p style="top:373.7pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Tirilazad</span></p>
<p style="top:373.7pt;left:213.9pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.85</span></p>
<p style="top:382.7pt;left:194.3pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">3.39 to</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.30)</span></p>
<p style="top:373.7pt;left:266.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.019</span></p>
<p style="top:391.6pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Vasospasm</span></p>
<p style="top:400.6pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">severity</span></p>
<p style="top:391.6pt;left:213.9pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.22</span></p>
<p style="top:400.6pt;left:194.3pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">4.20 to</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.23)</span></p>
<p style="top:391.6pt;left:266.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.029</span></p>
<p style="top:418.5pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Rat</span></p>
<p style="top:418.5pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Single versus</span></p>
<p style="top:427.5pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">double</span></p>
<p style="top:436.5pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Cisterna magna</span></p>
<p style="top:445.4pt;left:126.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">injection</span></p>
<p style="top:436.5pt;left:217.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">4.17</span></p>
<p style="top:445.4pt;left:200.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(0.76 to 7.59)</span></p>
<p style="top:436.5pt;left:266.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.017</span></p>
<img style="position:absolute;transform:matrix(.6399973,0,-0,.63974669,319.21937,-25.977356)" src="data:image/jpeg;base64,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">
<p style="top:382.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicB,serif;font-size:9.0pt">Figure 3</span><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt"> Begg&#x2019;s funnel plots with pseudo 95% confidence limits</span></p>
<p style="top:392.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt">for 74 (upper) or 114 (lower) dose regimen comparisons.</span></p>
<p style="top:34.3pt;left:302.9pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicB,serif;font-size:6.9pt">Experimental vasospasm models</span></p>
<p style="top:43.3pt;left:302.9pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicR,serif;font-size:6.9pt">T Zoerle</span><span style="font-family:AdvNewsGothicI,serif;font-size:6.9pt"> et al</span></p>
<p style="top:58.4pt;left:563.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1653</span></p>
<p style="top:749.4pt;left:384.2pt;line-height:7.1pt"><span style="font-family:AdvNewsGothicB,serif;font-size:7.1pt">Journal of Cerebral Blood Flow &amp; Metabolism (2012) 32, 1645&#x2013;1658</span></p>


<p style="top:504.6pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">endothelin antagonists had significant effects) of six</span></p>
<p style="top:515.6pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">(33%). One drug (fasudil had significant effect) of</span></p>
<p style="top:526.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">four (25%) was concordant in rats while in mice,</span></p>
<p style="top:537.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">none of two was concordant (Table 3). Considering</span></p>
<p style="top:548.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">animal studies individually, 55% were concordant.</span></p>
<p style="top:559.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">In multivariate logistic regression after using a</span></p>
<p style="top:570.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Bonferroni adjustment for multiple testing, the only</span></p>
<p style="top:581.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">significant predictor of translation was the day of</span></p>
<p style="top:592.3pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">assessment of vasospasm (continuous or dichoto-</span></p>
<p style="top:603.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">mized</span><span style="font-family:AdvEls,serif;font-size:10.0pt"> r</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> versus &gt; 3 days). Studies where vasospasm</span></p>
<p style="top:614.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">was evaluated after day 3 from SAH have results</span></p>
<p style="top:625.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">more concordant with human trials than others.</span></p>
<p style="top:636.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Univariate analysis showed angiographic evaluation</span></p>
<p style="top:647.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">of vasospasm (versus histology), intracranial delivery</span></p>
<p style="top:658.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">of drug (versus other routes), use of randomization,</span></p>
<p style="top:669.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">statement of inclusion and exclusion criteria, cister-</span></p>
<p style="top:679.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">nal injection procedure or fresh blood injection</span></p>
<p style="top:690.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">(versus clot placement), and blinding of assessment</span></p>
<p style="top:701.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">of outcome were associated with higher probability</span></p>
<p style="top:712.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">of translation (</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">P</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> &lt; 0.15; Table 4; Supplementary</span></p>
<p style="top:723.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Figure 1).</span></p>
<p style="top:506.2pt;left:302.9pt;line-height:13.0pt"><span style="font-family:AdvHelv_B,serif;font-size:13.0pt">Discussion</span></p>
<p style="top:526.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">This systematic review found that pharmacologic</span></p>
<p style="top:537.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">treatments that are effective at reducing vasospasm</span></p>
<p style="top:548.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">in animal models of SAH are also usually effective in</span></p>
<p style="top:559.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">humans. However, publication bias was detected,</span></p>
<p style="top:570.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">suggesting that some studies remain unpublished</span></p>
<p style="top:581.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">and that the data may overestimate the true effect of</span></p>
<p style="top:592.3pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">the drugs. Since one of the objectives of animal</span></p>
<p style="top:603.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">experimentation is to develop new treatment for</span></p>
<p style="top:614.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">human</span></p>
<p style="top:614.2pt;left:343.3pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">disease,</span></p>
<p style="top:614.2pt;left:387.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">lack</span></p>
<p style="top:614.2pt;left:414.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">of</span></p>
<p style="top:614.2pt;left:431.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">publishing</span></p>
<p style="top:614.2pt;left:489.6pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">of</span></p>
<p style="top:614.2pt;left:506.7pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">negative</span></p>
<p style="top:625.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">experimental studies may contribute substantially</span></p>
<p style="top:636.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">to unsuccessful translation of results to humans</span></p>
<p style="top:647.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">(Sena</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2010; van der Worp</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2010). On the</span></p>
<p style="top:658.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">other hand, methodologic quality of many of the</span></p>
<p style="top:669.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">studies was poor, and would limit the interpretation</span></p>
<p style="top:679.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">of experimental studies showing treatment benefits,</span></p>
<p style="top:690.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">as well as of those showing no benefit. We also found</span></p>
<p style="top:701.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">significant heterogeneity and that the effect size was</span></p>
<p style="top:712.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">related to some of the study characteristics. The type</span></p>
<p style="top:723.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">of SAH model for erythropoietin and statins, animal</span></p>
<p style="top:66.1pt;left:48.8pt;line-height:9.5pt"><span style="font-family:AdvNewsGothicB,serif;font-size:9.5pt">Table 3</span><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt"> Treatment effect of different drugs in different species</span></p>
<p style="top:86.0pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Species</span></p>
<p style="top:86.0pt;left:138.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Calcium</span></p>
<p style="top:95.0pt;left:138.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">channel</span></p>
<p style="top:103.9pt;left:134.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">antagonist</span></p>
<p style="top:86.0pt;left:197.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Statins</span></p>
<p style="top:86.0pt;left:243.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Erythropoietin</span></p>
<p style="top:86.0pt;left:317.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Tissue</span></p>
<p style="top:95.0pt;left:305.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">plasminogen</span></p>
<p style="top:103.9pt;left:313.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">activator</span></p>
<p style="top:86.0pt;left:369.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Tirilazad</span></p>
<p style="top:86.0pt;left:429.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Fasudil</span></p>
<p style="top:86.0pt;left:490.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Endothelin</span></p>
<p style="top:95.0pt;left:475.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">antagonist/enzyme</span></p>
<p style="top:104.0pt;left:494.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">inhibitor</span></p>
<p style="top:125.2pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Human</span></p>
<p style="top:125.2pt;left:145.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.85</span></p>
<p style="top:125.2pt;left:202.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.85</span></p>
<p style="top:125.2pt;left:262.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.85</span></p>
<p style="top:125.2pt;left:321.4pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.54</span></p>
<p style="top:125.2pt;left:378.3pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.92</span></p>
<p style="top:125.2pt;left:435.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.62</span></p>
<p style="top:125.2pt;left:502.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.60</span></p>
<p style="top:134.1pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Risk ratio (95% CI)</span></p>
<p style="top:134.1pt;left:135.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.66; 1.08</span></p>
<p style="top:134.1pt;left:192.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.55; 1.31</span></p>
<p style="top:134.1pt;left:251.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.51; 1.41</span></p>
<p style="top:134.1pt;left:311.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.33; 0.88</span></p>
<p style="top:134.1pt;left:368.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.76; 1.11</span></p>
<p style="top:134.1pt;left:424.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.46; 0.83</span></p>
<p style="top:134.1pt;left:492.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.50; 0.73</span></p>
<p style="top:143.1pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Monkey</span></p>
<p style="top:143.1pt;left:142.9pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.25</span></p>
<p style="top:143.1pt;left:191.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:143.1pt;left:251.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:143.1pt;left:318.3pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.77</span></p>
<p style="top:143.1pt;left:375.2pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.90</span></p>
<p style="top:143.1pt;left:424.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:143.1pt;left:499.5pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.26</span></p>
<p style="top:152.0pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Standard mean</span></p>
<p style="top:161.0pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">difference (95% CI)</span></p>
<p style="top:152.0pt;left:132.7pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.77; 0.28</span></p>
<p style="top:152.0pt;left:191.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:152.0pt;left:251.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:152.0pt;left:305.1pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">3.21;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.34</span></p>
<p style="top:152.0pt;left:362.0pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">4.60;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.19</span></p>
<p style="top:152.0pt;left:424.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:152.0pt;left:489.4pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.23; 1.71</span></p>
<p style="top:169.9pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Dog</span></p>
<p style="top:169.9pt;left:142.9pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.62</span></p>
<p style="top:169.9pt;left:199.7pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.97</span></p>
<p style="top:169.9pt;left:251.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:169.9pt;left:318.3pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">5.30</span></p>
<p style="top:169.9pt;left:375.2pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.54</span></p>
<p style="top:169.9pt;left:432.0pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">3.10</span></p>
<p style="top:169.9pt;left:499.5pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.66</span></p>
<p style="top:179.0pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Standard mean</span></p>
<p style="top:187.9pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">difference (95% CI)</span></p>
<p style="top:179.0pt;left:129.7pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.58;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.65</span></p>
<p style="top:179.0pt;left:189.6pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.38; 0.44</span></p>
<p style="top:179.0pt;left:251.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:179.0pt;left:305.1pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">8.43;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.18</span></p>
<p style="top:179.0pt;left:362.0pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">3.58;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.51</span></p>
<p style="top:179.0pt;left:418.8pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">4.73;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.47</span></p>
<p style="top:179.0pt;left:486.4pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.17;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.14</span></p>
<p style="top:196.9pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Rabbit</span></p>
<p style="top:196.9pt;left:142.9pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.89</span></p>
<p style="top:196.9pt;left:199.7pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">4.99</span></p>
<p style="top:196.9pt;left:259.0pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.29</span></p>
<p style="top:196.9pt;left:318.3pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.04</span></p>
<p style="top:196.9pt;left:375.2pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.21</span></p>
<p style="top:196.9pt;left:424.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:196.9pt;left:499.5pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.20</span></p>
<p style="top:205.8pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Standard mean</span></p>
<p style="top:214.8pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">difference (95% CI)</span></p>
<p style="top:205.8pt;left:129.7pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.58;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.19</span></p>
<p style="top:205.8pt;left:189.6pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">7.73; 2.25</span></p>
<p style="top:205.8pt;left:245.8pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">3.91;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.67</span></p>
<p style="top:205.8pt;left:305.1pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">3.84;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.24</span></p>
<p style="top:205.8pt;left:362.0pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">3.38;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.05</span></p>
<p style="top:205.8pt;left:424.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:205.8pt;left:486.4pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">3.22;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.18</span></p>
<p style="top:223.7pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Rat</span></p>
<p style="top:223.7pt;left:142.9pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.08</span></p>
<p style="top:223.7pt;left:199.7pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">3.51</span></p>
<p style="top:223.7pt;left:251.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:223.7pt;left:310.3pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:223.7pt;left:367.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:223.7pt;left:432.0pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.67</span></p>
<p style="top:223.7pt;left:499.5pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.42</span></p>
<p style="top:232.7pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Standard mean</span></p>
<p style="top:241.7pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">difference (95% CI)</span></p>
<p style="top:232.7pt;left:129.7pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.72;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.45</span></p>
<p style="top:232.7pt;left:186.5pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">6.21;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.80</span></p>
<p style="top:232.7pt;left:251.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:232.7pt;left:310.3pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:232.7pt;left:367.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:232.7pt;left:418.8pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">3.91;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.43</span></p>
<p style="top:232.7pt;left:489.4pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.35; 0.52</span></p>
<p style="top:250.7pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Mouse</span></p>
<p style="top:250.7pt;left:142.9pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">3.80</span></p>
<p style="top:250.7pt;left:199.7pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.46</span></p>
<p style="top:250.7pt;left:251.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:250.7pt;left:310.3pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:250.7pt;left:367.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:250.7pt;left:424.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:250.7pt;left:491.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:259.6pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Standard mean</span></p>
<p style="top:268.6pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">difference (95% CI)</span></p>
<p style="top:259.6pt;left:129.7pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">5.24;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.36</span></p>
<p style="top:259.6pt;left:186.5pt;line-height:8.0pt"><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.51;</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt"> &#xfffd;</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.40</span></p>
<p style="top:259.6pt;left:251.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:259.6pt;left:310.3pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:259.6pt;left:367.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:259.6pt;left:424.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:259.6pt;left:491.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not tested</span></p>
<p style="top:289.3pt;left:48.8pt;line-height:7.5pt"><span style="font-family:AdvNewsGothicR,serif;font-size:7.5pt">CI, confidence interval.</span></p>
<p style="top:315.3pt;left:48.8pt;line-height:9.5pt"><span style="font-family:AdvNewsGothicB,serif;font-size:9.5pt">Table 4</span><span style="font-family:AdvNewsGothicR,serif;font-size:9.0pt"> Results of univariate and multivariate logistic regression for predictors of translation</span></p>
<p style="top:335.1pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Variable</span></p>
<p style="top:335.1pt;left:259.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Univariate analysis</span></p>
<p style="top:335.1pt;left:423.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Multivariate analysis</span></p>
<p style="top:356.6pt;left:225.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">P</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">-value</span></p>
<p style="top:356.6pt;left:268.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Unadjusted odds ratio</span></p>
<p style="top:365.5pt;left:268.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(95% confidence interval)</span></p>
<p style="top:356.6pt;left:393.0pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">P</span><span style="font-family:AdvMelior,serif;font-size:8.0pt">-value</span></p>
<p style="top:356.6pt;left:449.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Unadjusted odds ratio</span></p>
<p style="top:365.5pt;left:449.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">(95% confidence interval)</span></p>
<p style="top:386.7pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Angiography versus histology</span></p>
<p style="top:386.7pt;left:227.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.0039</span></p>
<p style="top:386.7pt;left:284.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">5.04 (1.68; 15.11)</span></p>
<p style="top:386.7pt;left:379.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not significant</span></p>
<p style="top:395.7pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Fresh blood versus clot placement</span></p>
<p style="top:395.7pt;left:227.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.1490</span></p>
<p style="top:395.7pt;left:284.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.96 (0.65; 5.90)</span></p>
<p style="top:395.7pt;left:379.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not significant</span></p>
<p style="top:413.6pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Day of vasospasm evaluation</span></p>
<p style="top:422.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Continuous</span></p>
<p style="top:422.6pt;left:227.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.0056</span></p>
<p style="top:422.6pt;left:284.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.38 (1.10; 1.74)</span></p>
<p style="top:422.6pt;left:394.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.0006</span></p>
<p style="top:422.6pt;left:467.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1.62 (1.23; 2.14)</span></p>
<p style="top:431.5pt;left:58.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">&gt; 3 versus #3 days</span></p>
<p style="top:431.5pt;left:227.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.0019</span></p>
<p style="top:431.5pt;left:284.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">6.22 (1.96; 19.7)</span></p>
<p style="top:431.5pt;left:394.6pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.0002</span></p>
<p style="top:431.5pt;left:467.7pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">11.2 (3.13; 40.1)</span></p>
<p style="top:440.5pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Drug delivery (intracranial versus systemic)</span></p>
<p style="top:440.5pt;left:227.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.0750</span></p>
<p style="top:440.5pt;left:284.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">2.40 (0.92; 6.29)</span></p>
<p style="top:440.5pt;left:379.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not significant</span></p>
<p style="top:449.5pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Randomization</span></p>
<p style="top:449.5pt;left:227.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.1007</span></p>
<p style="top:449.5pt;left:284.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.46 (0.18; 1.16)</span></p>
<p style="top:449.5pt;left:379.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not significant</span></p>
<p style="top:458.5pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Blinding outcome</span></p>
<p style="top:458.5pt;left:227.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.1149</span></p>
<p style="top:458.5pt;left:284.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.46 (0.18; 1.21)</span></p>
<p style="top:458.5pt;left:379.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not significant</span></p>
<p style="top:467.4pt;left:48.8pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Inclusion/exclusion criteria</span></p>
<p style="top:467.4pt;left:227.1pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.0578</span></p>
<p style="top:467.4pt;left:284.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">0.20 (0.04; 1.05)</span></p>
<p style="top:467.4pt;left:379.5pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">Not significant</span></p>
<p style="top:34.3pt;left:206.8pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicB,serif;font-size:6.9pt">Experimental vasospasm models</span></p>
<p style="top:43.3pt;left:256.6pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicR,serif;font-size:6.9pt">T Zoerle</span><span style="font-family:AdvNewsGothicI,serif;font-size:6.9pt"> et al</span></p>
<p style="top:58.4pt;left:12.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1654</span></p>
<p style="top:749.4pt;left:12.9pt;line-height:7.1pt"><span style="font-family:AdvNewsGothicB,serif;font-size:7.1pt">Journal of Cerebral Blood Flow &amp; Metabolism (2012) 32, 1645&#x2013;1658</span></p>


<p style="top:66.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">species</span></p>
<p style="top:66.2pt;left:90.5pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">for</span></p>
<p style="top:66.2pt;left:111.5pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">calcium</span></p>
<p style="top:66.2pt;left:156.4pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">channel</span></p>
<p style="top:66.2pt;left:201.4pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">antagonists,</span></p>
<p style="top:66.2pt;left:264.2pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">tissue</span></p>
<p style="top:77.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">plasminogen activator for dogs, tirilizad and severity</span></p>
<p style="top:88.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">of vasospasm for monkeys were significantly differ-</span></p>
<p style="top:99.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">ent. This observation suggests that results of experi-</span></p>
<p style="top:110.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">mental studies are related not only to the drug tested</span></p>
<p style="top:121.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">but also to the study design and quality and that</span></p>
<p style="top:132.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">these factors should be considered when evaluating</span></p>
<p style="top:142.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">whether to test a drug in humans.</span></p>
<p style="top:153.9pt;left:58.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">The other main objective of this work was to assess</span></p>
<p style="top:164.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">if any animal used in models of SAH more accurately</span></p>
<p style="top:175.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">reflects results of human studies. We observed that</span></p>
<p style="top:186.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">not every drug is effective in every species and that</span></p>
<p style="top:197.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">in monkey and dog studies the concordance with</span></p>
<p style="top:208.7pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">human studies was higher. However, in multivariate</span></p>
<p style="top:219.7pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">logistic regression after adjustment for multiple</span></p>
<p style="top:230.7pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">testing, only the day of evaluation of vasospasm</span></p>
<p style="top:241.6pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">( &gt; 3 days after SAH) correlated with successful</span></p>
<p style="top:252.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">translation of results to humans. These observations</span></p>
<p style="top:263.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">have practical implications for study design and</span></p>
<p style="top:274.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">model selection and it may be that in further</span></p>
<p style="top:285.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">preclinical experiments long-term drug effect evalua-</span></p>
<p style="top:296.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">tion should be preferred.</span></p>
<p style="top:307.4pt;left:58.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">There are a number of limitations to this analysis.</span></p>
<p style="top:318.3pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Most instances of concordance were positive, in that</span></p>
<p style="top:329.3pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">drugs worked in animals and humans. However,</span></p>
<p style="top:340.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">additional important confirmatory data would be</span></p>
<p style="top:351.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">studies showing that drugs that were not effective in</span></p>
<p style="top:362.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">humans also were not in animals. In studies that</span></p>
<p style="top:373.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">show no effect, drug dose, timing and route of</span></p>
<p style="top:384.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">administration would also need to be fully explored</span></p>
<p style="top:395.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">or at least shown to be equivalent between animal</span></p>
<p style="top:406.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">and human studies. There are limited data on some</span></p>
<p style="top:417.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">models, such as rats and mice. Only 11 of the 72</span></p>
<p style="top:427.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">(15%) studies used rats or mice, and almost all recent</span></p>
<p style="top:438.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">studies use them. Given the paucity of data, we</span></p>
<p style="top:449.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">cannot exclude the possibility that these models are</span></p>
<p style="top:460.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">equal to dogs and monkeys in terms of translation of</span></p>
<p style="top:471.7pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">results to human. In human trials, angiographic</span></p>
<p style="top:482.7pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">vasospasm frequently was considered as a dichot-</span></p>
<p style="top:493.7pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">omous</span></p>
<p style="top:493.7pt;left:87.5pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">variable</span></p>
<p style="top:493.7pt;left:132.1pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">(none/mild</span></p>
<p style="top:493.7pt;left:191.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">or</span></p>
<p style="top:493.7pt;left:209.5pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">moderate/severe),</span></p>
<p style="top:504.6pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">while</span></p>
<p style="top:504.6pt;left:83.0pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">in</span></p>
<p style="top:504.6pt;left:100.6pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">animal</span></p>
<p style="top:504.6pt;left:140.3pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">studies,</span></p>
<p style="top:504.6pt;left:184.0pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">it</span></p>
<p style="top:504.6pt;left:198.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">is</span></p>
<p style="top:504.6pt;left:214.7pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">expressed</span></p>
<p style="top:504.6pt;left:268.3pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">as</span></p>
<p style="top:515.6pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">continuous variable. For this reason, it was not</span><sup><span style="font-family:AdvMelior,serif;font-size:10.0pt">a</span></sup></p>
<p style="top:526.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">possible to compare exactly the effects in animals</span></p>
<p style="top:537.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">and humans. We focused on prophylactic treatments</span></p>
<p style="top:548.5pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">and in the human studies, drugs were administered</span></p>
<p style="top:559.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">before the onset of angiographic vasospasm. In the</span></p>
<p style="top:570.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">animal studies, however, since we included some</span></p>
<p style="top:581.4pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">studies where drug administration began after the</span></p>
<p style="top:592.3pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">second blood injection and angiography was not</span></p>
<p style="top:603.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">done, it is possible that some of these studies were</span></p>
<p style="top:614.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">also treating established vasospasm. The classifica-</span></p>
<p style="top:625.2pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">tion of drugs also could be questioned. We categor-</span></p>
<p style="top:636.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">ized magnesium separately since it has calcium</span></p>
<p style="top:647.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">antagonist</span></p>
<p style="top:647.1pt;left:104.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">and</span></p>
<p style="top:647.1pt;left:130.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">putative</span></p>
<p style="top:647.1pt;left:177.3pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">neuroprotective</span></p>
<p style="top:647.1pt;left:258.7pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">effects.</span></p>
<p style="top:658.1pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Another option would be to include it in the calcium</span></p>
<p style="top:669.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">antagonist category. For calcium antagonists, we</span></p>
<p style="top:680.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">searched only for nimodipine and nicardipine since</span></p>
<p style="top:691.0pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">other calcium antagonists have not been studied in</span></p>
<p style="top:701.9pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">randomized clinical trials in humans.</span></p>
<p style="top:712.8pt;left:58.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Another issue is the analysis was restricted to</span></p>
<p style="top:723.8pt;left:48.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">evaluation of angiographic or large-artery vasospasm.</span></p>
<p style="top:66.3pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">Most models of SAH differ from human SAH in that</span></p>
<p style="top:77.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">animals do not develop cerebral infarctions or other</span></p>
<p style="top:88.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">delayed processes that are proposed to be important</span></p>
<p style="top:99.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">in humans, such as cortical spreading ischemia and</span></p>
<p style="top:110.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">microthromboembolism (Dreier</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2009; Vergou-</span></p>
<p style="top:121.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">wen</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2008). The end points in human clinical</span></p>
<p style="top:132.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">trials are usually clinical outcome and delayed</span></p>
<p style="top:143.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">cerebral ischemia but neurological and functional</span></p>
<p style="top:154.0pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">examination after experimental SAH is still uncom-</span></p>
<p style="top:164.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">monly used (Jeon</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2009; Takata</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2008).</span></p>
<p style="top:175.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">There is some evidence that reduction of angio-</span></p>
<p style="top:186.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">graphic vasospasm does not correlate with improved</span></p>
<p style="top:197.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">outcome in humans (Etminan</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2011; Macdo-</span></p>
<p style="top:208.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">nald, 2011; Macdonald</span><span style="font-family:AdvMelior,serif;font-size:10.0pt"> et al</span><span style="font-family:AdvMelior,serif;font-size:10.0pt">, 2008). Unfortunately, if</span></p>
<p style="top:219.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">this is true and not due to other reasons, such as</span></p>
<p style="top:230.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">efficacy of rescue therapy in placebo groups, insen-</span></p>
<p style="top:241.6pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">sitive outcome measures, drug side-effects and such,</span></p>
<p style="top:252.6pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">animal models will have to be reassessed to ensure</span></p>
<p style="top:263.6pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">they reflect relevant human features if they are to be</span></p>
<p style="top:274.5pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">used to decide whether to advance drugs into clinical</span></p>
<p style="top:285.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">trials. The present analysis focused on angiographic</span></p>
<p style="top:296.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">vasospasm but subsequent analysis might examine</span></p>
<p style="top:307.4pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">the relation between delayed cerebral ischemia and</span></p>
<p style="top:318.3pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">neurological outcome in animals and humans.</span></p>
<p style="top:329.3pt;left:312.8pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">In conclusion, we found evidence that animal</span></p>
<p style="top:340.3pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">models can inform effects of pharmacologic treat-</span></p>
<p style="top:351.2pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">ments for angiographic vasospasm in human clinical</span></p>
<p style="top:362.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">trials. Higher species, longer durations of assessment</span></p>
<p style="top:373.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">of vasospasm and injections of fresh blood may be</span></p>
<p style="top:384.1pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">more applicable.</span></p>
<p style="top:412.3pt;left:302.9pt;line-height:12.0pt"><span style="font-family:AdvHelv_B,serif;font-size:12.0pt">Disclosure/conflict of interest</span></p>
<p style="top:431.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">RL Macdonald is a consultant for Actelion Pharma-</span></p>
<p style="top:442.9pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">ceuticals and Chief Scientific Officer of Edge Thera-</span></p>
<p style="top:453.8pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">peutics, Inc. Edge Therapeutics is dedicated to</span></p>
<p style="top:464.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">developing drugs to improve outcome of patients</span></p>
<p style="top:475.7pt;left:302.9pt;line-height:10.0pt"><span style="font-family:AdvMelior,serif;font-size:10.0pt">with subarachnoid hemorrhage and brain injuries.</span></p>
<p style="top:513.7pt;left:302.9pt;line-height:13.0pt"><span style="font-family:AdvHelv_B,serif;font-size:13.0pt">References</span></p>
<p style="top:535.3pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Bilginer B, Onal MB, Narin F, Soylemezoglu F, Ziyal IM,</span></p>
<p style="top:545.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Ozgen T (2009) The effects of intravenous cilostazol and</span></p>
<p style="top:555.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">nimodipine on cerebral vasospasm after subarachnoid</span></p>
<p style="top:565.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">hemorrhage in an experimental rabbit model.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Turk</span></p>
<p style="top:575.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Neurosurg</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 19:374&#x2013;9</span></p>
<p style="top:585.1pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Bulsara KR, Coates JR, Agrawal VK, Eifler DM, Wagner-</span></p>
<p style="top:595.1pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Mann CC, Durham HE, Fine DM, Toft K (2006) Effect of</span></p>
<p style="top:605.1pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">combined simvastatin and cyclosporine compared with</span></p>
<p style="top:615.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">simvastatin alone on cerebral vasospasm after subar-</span></p>
<p style="top:625.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">achnoid hemorrhage in a canine model.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurg</span></p>
<p style="top:634.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Focus</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 21:E11</span></p>
<p style="top:644.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Caner HH, Kwan AL, Arthur A, Jeng AY, Lappe RW, Kassell</span></p>
<p style="top:654.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">NF, Lee KS (1996) Systemic administration of an</span></p>
<p style="top:664.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">inhibitor of endothelin-converting enzyme for attenua-</span></p>
<p style="top:674.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">tion of cerebral vasospasm following experimental</span></p>
<p style="top:684.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Neurosurg</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 85:917&#x2013;22</span></p>
<p style="top:694.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Chang CZ, Wu SC, Lin CL, Hwang SL, Howng SL, Kwan AL</span></p>
<p style="top:704.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(2010)</span></p>
<p style="top:704.7pt;left:348.7pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Atorvastatin</span></p>
<p style="top:704.7pt;left:407.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">preconditioning</span></p>
<p style="top:704.7pt;left:481.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">attenuates</span></p>
<p style="top:704.7pt;left:531.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">the</span></p>
<p style="top:714.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">production of endothelin-1 and prevents experimental</span></p>
<p style="top:724.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm in rats.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Acta Neurochir (Wien)</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 152:1399&#x2013;406</span></p>
<p style="top:34.3pt;left:302.9pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicB,serif;font-size:6.9pt">Experimental vasospasm models</span></p>
<p style="top:43.3pt;left:302.9pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicR,serif;font-size:6.9pt">T Zoerle</span><span style="font-family:AdvNewsGothicI,serif;font-size:6.9pt"> et al</span></p>
<p style="top:58.4pt;left:563.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1655</span></p>
<p style="top:749.4pt;left:384.2pt;line-height:7.1pt"><span style="font-family:AdvNewsGothicB,serif;font-size:7.1pt">Journal of Cerebral Blood Flow &amp; Metabolism (2012) 32, 1645&#x2013;1658</span></p>


<p style="top:66.1pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Chen G, Zhang S, Shi J, Ai J, Hang C (2009) Effects of</span></p>
<p style="top:76.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">recombinant human erythropoietin (rhEPO) on JAK2/</span></p>
<p style="top:86.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">STAT3 pathway and endothelial apoptosis in the rabbit</span></p>
<p style="top:96.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">basilar artery after subarachnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Cytokine</span></p>
<p style="top:105.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">45:162&#x2013;8</span></p>
<p style="top:115.9pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Cheng G, Wei L, Zhi-Dan S, Shi-Guang Z, Xiang-Zhen L</span></p>
<p style="top:125.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(2009) Atorvastatin ameliorates cerebral vasospasm and</span></p>
<p style="top:135.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">early brain injury after subarachnoid hemorrhage and</span></p>
<p style="top:145.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">inhibits caspase-dependent apoptosis pathway.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> BMC</span></p>
<p style="top:155.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Neurosci</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 10:7</span></p>
<p style="top:165.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Chung WY, Lee LS (1993) The effect of tissue plasminogen</span></p>
<p style="top:175.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">activator</span></p>
<p style="top:175.7pt;left:104.4pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(t-PA)</span></p>
<p style="top:175.7pt;left:135.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">on</span></p>
<p style="top:175.7pt;left:154.3pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cerebral</span></p>
<p style="top:175.7pt;left:194.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm</span></p>
<p style="top:175.7pt;left:247.1pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">in</span></p>
<p style="top:175.7pt;left:263.4pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">canine</span></p>
<p style="top:185.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Chung Hua i Hsueh Tsa</span></p>
<p style="top:195.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Chih</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 52:298&#x2013;306</span></p>
<p style="top:205.5pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Cosentino F, McMahon EG, Carter JS, Katusic ZS (1993)</span></p>
<p style="top:215.5pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Effect of endothelinA-receptor antagonist BQ-123 and</span></p>
<p style="top:225.4pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">phosphoramidon on cerebral vasospasm.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Cardiovasc</span></p>
<p style="top:235.4pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Pharmacol</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 22(Suppl 8):S332&#x2013;5</span></p>
<p style="top:245.4pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Crowley RW, Medel R, Dumont AS, Ilodigwe D, Kassell NF,</span></p>
<p style="top:255.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Mayer SA, Ruefenacht D, Schmiedek P, Weidauer S,</span></p>
<p style="top:265.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Pasqualin A, Macdonald RL (2011) Angiographic vasos-</span></p>
<p style="top:275.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">pasm is strongly correlated with cerebral infarction after</span></p>
<p style="top:285.2pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Stroke</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 42:919&#x2013;23</span></p>
<p style="top:295.2pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Dreier JP, Major S, Manning A, Woitzik J, Drenckhahn C,</span></p>
<p style="top:305.1pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Steinbrink J, Tolias C, Oliveira-Ferreira AI, Fabricius M,</span></p>
<p style="top:315.1pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Hartings JA, Vajkoczy P, Lauritzen M, Dirnagl U, Bohner</span></p>
<p style="top:325.1pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">G, Strong AJ (2009) Cortical spreading ischaemia is a</span></p>
<p style="top:335.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">novel process involved in ischaemic damage in patients</span></p>
<p style="top:345.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">with</span></p>
<p style="top:345.0pt;left:87.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">aneurysmal</span></p>
<p style="top:345.0pt;left:142.2pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid</span></p>
<p style="top:345.0pt;left:205.3pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">haemorrhage.</span></p>
<p style="top:345.0pt;left:268.4pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Brain</span></p>
<p style="top:355.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">132:1866&#x2013;81</span></p>
<p style="top:365.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Espinosa F, Weir B, Overton T, Castor W, Grace M, Boisvert</span></p>
<p style="top:374.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">D (1984) A randomized placebo-controlled double-blind</span></p>
<p style="top:384.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">trial of nimodipine after SAH in monkeys. Part 1:</span></p>
<p style="top:394.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">clinical and radiological findings.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Neurosurg</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 60:</span></p>
<p style="top:404.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">1167&#x2013;1175</span></p>
<p style="top:414.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Etminan N, Vergouwen MD, Ilodigwe D, Macdonald RL</span></p>
<p style="top:424.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(2011) Effect of pharmaceutical treatment on vasospasm,</span></p>
<p style="top:434.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">delayed cerebral ischemia, and clinical outcome in</span></p>
<p style="top:444.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">patients with aneurysmal subarachnoid hemorrhage: a</span></p>
<p style="top:454.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">systematic review and meta-analysis.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Cereb Blood</span></p>
<p style="top:464.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Flow Metab</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 31:1443&#x2013;51</span></p>
<p style="top:474.5pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Fergusen S, Macdonald RL (2007) Predictors of cerebral</span></p>
<p style="top:484.5pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">infarction in patients with aneurysmal subarachnoid</span></p>
<p style="top:494.4pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 60:658&#x2013;67</span></p>
<p style="top:504.4pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Findlay JM, Weir BK, Gordon P, Grace M, Baughman R</span></p>
<p style="top:514.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(1989) Safety and efficacy of intrathecal thrombolytic</span></p>
<p style="top:524.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">therapy in a primate model of cerebral vasospasm.</span></p>
<p style="top:534.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 24:491&#x2013;8</span></p>
<p style="top:544.3pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Findlay JM, Weir BK, Kanamaru K, Grace M, Baughman R</span></p>
<p style="top:554.2pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(1990) The effect of timing of intrathecal fibrinolytic</span></p>
<p style="top:564.2pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">therapy on cerebral vasospasm in a primate model of</span></p>
<p style="top:574.1pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 26:201&#x2013;6</span></p>
<p style="top:584.1pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Findlay JM, Weir BK, Steinke D, Tanabe T, Gordon P, Grace</span></p>
<p style="top:594.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">M (1988) Effect of intrathecal thrombolytic therapy on</span></p>
<p style="top:604.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid clot and chronic vasospasm in a primate</span></p>
<p style="top:614.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">model of SAH.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Neurosurg</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 69:723&#x2013;35</span></p>
<p style="top:623.9pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Grasso G, Buemi M, Alafaci C, Sfacteria A, Passalacqua M,</span></p>
<p style="top:633.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Sturiale A, Calapai G, De VG, Piedimonte G, Salpietro</span></p>
<p style="top:643.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">FM, Tomasello F (2002) Beneficial effects of systemic</span></p>
<p style="top:653.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">administration of recombinant human erythropoietin in</span></p>
<p style="top:663.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">rabbits subjected to subarachnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Proc</span></p>
<p style="top:673.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Natl Acad Sci USA</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 99:5627&#x2013;31</span></p>
<p style="top:683.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Gul S, Bahadir B, Hanci V, Acikgoz S, Bektas S, Ugurbas E,</span></p>
<p style="top:693.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Ankarali H, Kalayci M, Acikgoz B (2010) Effects of</span></p>
<p style="top:703.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">ebselen</span></p>
<p style="top:703.6pt;left:99.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">versus</span></p>
<p style="top:703.6pt;left:132.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">nimodipine</span></p>
<p style="top:703.6pt;left:188.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">on</span></p>
<p style="top:703.6pt;left:206.4pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cerebral</span></p>
<p style="top:703.6pt;left:246.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm</span></p>
<p style="top:713.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subsequent to experimental subarachnoid hemorrhage</span></p>
<p style="top:723.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">in rats.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Clin Neurosci</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 17:608&#x2013;11</span></p>
<p style="top:66.1pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Hanggi D, Eicker S, Beseoglu K, Rapp M, Perrin J, Nawatny</span></p>
<p style="top:76.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">J, Turowski B, Sommer C, Steiger HJ (2009) Dose-related</span></p>
<p style="top:86.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">efficacy</span></p>
<p style="top:86.0pt;left:353.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">of</span></p>
<p style="top:86.0pt;left:369.1pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">a</span></p>
<p style="top:86.0pt;left:380.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">continuous</span></p>
<p style="top:86.0pt;left:434.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">intracisternal</span></p>
<p style="top:86.0pt;left:496.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">nimodipine</span></p>
<p style="top:95.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">treatment on cerebral vasospasm in the rat double</span></p>
<p style="top:105.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid</span></p>
<p style="top:105.9pt;left:384.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">hemorrhage</span></p>
<p style="top:105.9pt;left:447.2pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">model.</span></p>
<p style="top:105.9pt;left:489.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Neurosurgery</span></p>
<p style="top:115.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">64:1155&#x2013;9</span></p>
<p style="top:125.8pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Hariton GB, Findlay JM, Weir BK, Kasuya H, Grace MG,</span></p>
<p style="top:135.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Mielke BW (1993) Comparison of intrathecal adminis-</span></p>
<p style="top:145.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">tration of urokinase and tissue plasminogen activator on</span></p>
<p style="top:155.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid clot and chronic vasospasm in a primate</span></p>
<p style="top:165.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">model.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 33:691&#x2013;6</span></p>
<p style="top:175.6pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Higgins</span></p>
<p style="top:175.6pt;left:342.3pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">J,</span></p>
<p style="top:175.6pt;left:355.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Green</span></p>
<p style="top:175.6pt;left:388.2pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">S</span></p>
<p style="top:175.6pt;left:401.7pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(2008)</span></p>
<p style="top:175.6pt;left:435.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Cochrane</span></p>
<p style="top:175.6pt;left:482.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Handbook</span></p>
<p style="top:175.6pt;left:533.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">for</span></p>
<p style="top:185.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Systematic Reviews of Interventions</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">. The Cochrane</span></p>
<p style="top:195.5pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Collaboration</span></p>
<p style="top:195.5pt;left:383.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Available</span></p>
<p style="top:195.5pt;left:433.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">at</span></p>
<p style="top:195.5pt;left:453.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">http://www.cochrane-</span></p>
<p style="top:205.5pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">handbook.org</span></p>
<p style="top:215.5pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Hino A, Weir BK, Macdonald RL, Thisted RA, Kim CJ,</span></p>
<p style="top:225.4pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Johns LM (1995) Prospective, randomized, double-blind</span></p>
<p style="top:235.4pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">trial of BQ-123 and bosentan for prevention of vasos-</span></p>
<p style="top:245.4pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">pasm following subarachnoid hemorrhage in monkeys.</span></p>
<p style="top:255.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">J Neurosurg</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 83:503&#x2013;9</span></p>
<p style="top:265.3pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Itoh S, Sasaki T, Asai A, Kuchino Y (1994) Prevention of</span></p>
<p style="top:275.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">delayed vasospasm by an endothelin ETA receptor</span></p>
<p style="top:285.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">antagonist, BQ-123: change of ETA receptor mRNA</span></p>
<p style="top:295.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">expression in a canine subarachnoid hemorrhage mod-</span></p>
<p style="top:305.1pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">el.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Neurosurg</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 81:759&#x2013;64</span></p>
<p style="top:315.1pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Itoh S, Sasaki T, Ide K, Ishikawa K, Nishikibe M, Yano M</span></p>
<p style="top:325.1pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(1993) A novel endothelin ETA receptor antagonist, BQ-</span></p>
<p style="top:335.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">485, and its preventive effect on experimental cerebral</span></p>
<p style="top:345.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm</span></p>
<p style="top:345.0pt;left:366.7pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">in</span></p>
<p style="top:345.0pt;left:382.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">dogs.</span></p>
<p style="top:345.0pt;left:411.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Biochem</span></p>
<p style="top:345.0pt;left:455.3pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Biophys</span></p>
<p style="top:345.0pt;left:496.1pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Res</span></p>
<p style="top:345.0pt;left:518.2pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Comm</span></p>
<p style="top:355.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">195:969&#x2013;75</span></p>
<p style="top:365.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Jeon H, Ai J, Sabri M, Tariq A, Shang X, Chen G,</span></p>
<p style="top:374.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Macdonald RL (2009) Neurological and neurobehavioral</span></p>
<p style="top:384.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">assessment of experimental subarachnoid hemorrhage.</span></p>
<p style="top:394.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">BMC Neurosci</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 10:103</span></p>
<p style="top:404.8pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Josko J, Hendryk S, Jedrzejowska-Szypulka H, Slowinski J,</span></p>
<p style="top:414.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Gwozdz B, Lange D, Harabin-Slowinska M (2000) Effect</span></p>
<p style="top:424.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">of endothelin-1 receptor antagonist BQ-123 on basilar</span></p>
<p style="top:434.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">artery diameter after subarachnoid hemorrhage (SAH) in</span></p>
<p style="top:444.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">rats.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Physiol Pharmacol</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 51:241&#x2013;9</span></p>
<p style="top:454.6pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Kanamaru K, Weir BK, Findlay JM, Grace M, Macdonald</span></p>
<p style="top:464.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">RL (1990) A dosage study of the effect of the 21-</span></p>
<p style="top:474.5pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">aminosteroid U74006F on chronic cerebral vasospasm</span></p>
<p style="top:484.5pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">in a primate model.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 27:29&#x2013;38</span></p>
<p style="top:494.4pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Kanamaru K, Weir BK, Simpson I, Witbeck T, Grace M</span></p>
<p style="top:504.4pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(1991) Effect of 21-aminosteroid U-74006F on lipid</span></p>
<p style="top:514.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">peroxidation in subarachnoid clot.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Neurosurg</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 74:</span></p>
<p style="top:524.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">454&#x2013;459</span></p>
<p style="top:534.3pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Kawada S, Kinugasa K, Meguro T, Hirotsune N, Tokunaga</span></p>
<p style="top:544.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">K, Kamata I, Nakashima H, Ohmoto T (1999) Experi-</span></p>
<p style="top:554.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">mental study of intracisternal administration of tissue-</span></p>
<p style="top:564.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">type plasminogen activator followed by cerebrospinal</span></p>
<p style="top:574.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">fluid drainage in the ultra-early stage of subarachnoid</span></p>
<p style="top:584.1pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">haemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Acta Neurochir</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 141:1331&#x2013;8</span></p>
<p style="top:594.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Kawashima A, Kasuya H, Sasahara A, Miyajima M, Izawa</span></p>
<p style="top:604.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">M, Hori T (2000) Prevention of cerebral vasospasm by</span></p>
<p style="top:614.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">nicardipine prolonged-release implants in dogs.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurol</span></p>
<p style="top:623.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Res</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 22:634&#x2013;41</span></p>
<p style="top:633.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Kim CJ, Bassiouny M, Macdonald RL, Weir B, Johns LM</span></p>
<p style="top:643.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(1996) Effect of BQ-123 and tissue plasminogen activa-</span></p>
<p style="top:653.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">tor on vasospasm after subarachnoid hemorrhage in</span></p>
<p style="top:663.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">monkeys.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Stroke</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 27:1629&#x2013;33</span></p>
<p style="top:673.8pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Kim I, Leinweber BD, Morgalla M, Butler WE, Seto M,</span></p>
<p style="top:683.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Sasaki Y, Peterson JW, Morgan KG (2000) Thin and thick</span></p>
<p style="top:693.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">filament regulation of contractility in experimental</span></p>
<p style="top:703.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cerebral vasospasm.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 46:440&#x2013;7</span></p>
<p style="top:713.6pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Kita T, Kubo K, Hiramatsu K, Sakaki T, Yonetani Y, Sato S,</span></p>
<p style="top:723.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Fujimoto</span></p>
<p style="top:723.6pt;left:360.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">M,</span></p>
<p style="top:723.6pt;left:378.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Nakashima</span></p>
<p style="top:723.6pt;left:432.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">T</span></p>
<p style="top:723.6pt;left:446.3pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(1998)</span></p>
<p style="top:723.6pt;left:480.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Profiles</span></p>
<p style="top:723.6pt;left:519.2pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">of</span></p>
<p style="top:723.6pt;left:534.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">an</span></p>
<p style="top:34.3pt;left:206.8pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicB,serif;font-size:6.9pt">Experimental vasospasm models</span></p>
<p style="top:43.3pt;left:256.6pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicR,serif;font-size:6.9pt">T Zoerle</span><span style="font-family:AdvNewsGothicI,serif;font-size:6.9pt"> et al</span></p>
<p style="top:58.4pt;left:12.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1656</span></p>
<p style="top:749.4pt;left:12.9pt;line-height:7.1pt"><span style="font-family:AdvNewsGothicB,serif;font-size:7.1pt">Journal of Cerebral Blood Flow &amp; Metabolism (2012) 32, 1645&#x2013;1658</span></p>


<p style="top:66.1pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">intravenously available endothelin A-receptor antago-</span></p>
<p style="top:76.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">nist, S-0139, for preventing cerebral vasospasm in a</span></p>
<p style="top:86.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">canine two-hemorrhage model.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Life Sci</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 63:305&#x2013;15</span></p>
<p style="top:96.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Kwan AL, Bavbek M, Jeng AY, Maniara W, Toyoda T, Lappe</span></p>
<p style="top:105.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">RW, Kassell NF, Lee KS (1997) Prevention and reversal</span></p>
<p style="top:115.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">of cerebral vasospasm by an endothelin-converting</span></p>
<p style="top:125.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">enzyme inhibitor, CGS 26303, in an experimental model</span></p>
<p style="top:135.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">of subarachnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Neurosurg</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 87:281&#x2013;6</span></p>
<p style="top:145.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Kwan AL, Lin CL, Chang CZ, Wu HJ, Hwong SL, Jeng AY,</span></p>
<p style="top:155.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Lee KS (2001) Continuous intravenous infusion of CGS</span></p>
<p style="top:165.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">26303,</span></p>
<p style="top:165.7pt;left:95.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">an</span></p>
<p style="top:165.7pt;left:113.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">endothelin-converting</span></p>
<p style="top:165.7pt;left:212.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">enzyme</span></p>
<p style="top:165.7pt;left:252.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">inhibitor,</span></p>
<p style="top:175.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">prevents and reverses cerebral vasospasm after experi-</span></p>
<p style="top:185.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">mental</span></p>
<p style="top:185.6pt;left:102.2pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid</span></p>
<p style="top:185.6pt;left:171.1pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">hemorrhage.</span></p>
<p style="top:185.6pt;left:235.4pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Neurosurgery</span></p>
<p style="top:195.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">49:422&#x2013;7</span></p>
<p style="top:205.5pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Kwan AL, Lin CL, Yen CP, Winardi W, Su YF, Winardi D,</span></p>
<p style="top:215.5pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Dai ZK, Jeng AY, Kassell NF, Howng SL, Wang CJ (2006)</span></p>
<p style="top:225.4pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Prevention and reversal of vasospasm and ultrastructur-</span></p>
<p style="top:235.4pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">al changes in basilar artery by continuous infusion of</span></p>
<p style="top:245.4pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">CGS 35066 following subarachnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Exp</span></p>
<p style="top:255.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Biol Med (Maywood)</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 231:1069&#x2013;74</span></p>
<p style="top:265.3pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Laslo AM, Eastwood JD, Chen FX, Lee TY (2006) Dynamic</span></p>
<p style="top:275.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">CT perfusion imaging in subarachnoid hemorrhage-</span></p>
<p style="top:285.2pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">related vasospasm.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> AJNR</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 27:624&#x2013;31</span></p>
<p style="top:295.2pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Lewis PJ, Weir BK, Nosko MG, Tanabe T, Grace MG (1988)</span></p>
<p style="top:305.1pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Intrathecal nimodipine therapy in a primate model of</span></p>
<p style="top:315.1pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">chronic cerebral vasospasm.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 22:492&#x2013;500</span></p>
<p style="top:325.1pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC,</span></p>
<p style="top:335.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher</span></p>
<p style="top:345.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">D (2009) The PRISMA statement for reporting systema-</span></p>
<p style="top:355.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">tic reviews and meta-analyses of studies that evaluate</span></p>
<p style="top:365.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">healthcare interventions: explanation and elaboration.</span></p>
<p style="top:374.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">BMJ</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 339:b2700</span></p>
<p style="top:384.9pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Lin CL, Kwan AL, Dumont AS, Su YF, Kassell NF, Wang CJ,</span></p>
<p style="top:394.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Wu SC, Kuo CL, Huang CS, Jeng AY, Liu CS (2007)</span></p>
<p style="top:404.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Attenuation of experimental subarachnoid hemorrhage-</span></p>
<p style="top:414.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">induced increases in circulating intercellular adhesion</span></p>
<p style="top:424.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">molecule-1 and cerebral vasospasm by the endothelin-</span></p>
<p style="top:434.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">converting enzyme inhibitor CGS 26303.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Neurosurg</span></p>
<p style="top:444.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">106:442&#x2013;8</span></p>
<p style="top:454.6pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Macdonald RL (2011) Predicting vasospasm after subar-</span></p>
<p style="top:464.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">achnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> World Neurosurg</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 75:25&#x2013;6</span></p>
<p style="top:474.5pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Macdonald RL, Bassiouny M, Johns L, Sajdak M, Marton</span></p>
<p style="top:484.5pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">LS, Weir BK, Hall ED, Andrus PK (1998a) U74389G</span></p>
<p style="top:494.4pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">prevents vasospasm after subarachnoid hemorrhage in</span></p>
<p style="top:504.4pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">dogs.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 42:1339&#x2013;45</span></p>
<p style="top:514.3pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Macdonald RL, Curry DJ, Aihara Y, Zhang ZD, Jahromi BS,</span></p>
<p style="top:524.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Yassari R (2004) Magnesium and experimental vasos-</span></p>
<p style="top:534.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">pasm.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Neurosurg</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 100:106&#x2013;10</span></p>
<p style="top:544.3pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Macdonald RL, Johns L, Lin G, Marton LS, Hallak H,</span></p>
<p style="top:554.2pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Marcoux F, Kowalczuk A (1998b) Prevention of vasos-</span></p>
<p style="top:564.2pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">pasm after subarachnoid hemorrhage in dogs by con-</span></p>
<p style="top:574.1pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">tinuous intravenous infusion of PD156707.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurologia</span></p>
<p style="top:584.1pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Medico-Chirurgica</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 38(Suppl):138&#x2013;45</span></p>
<p style="top:594.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Macdonald RL, Kassell NF, Mayer S, Ruefenacht D,</span></p>
<p style="top:604.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Schmiedek P, Weidauer S, Frey A, Roux S, Pasqualin</span></p>
<p style="top:614.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">A (2008) Clazosentan to overcome neurological ische-</span></p>
<p style="top:623.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">mia and infarction occurring after subarachnoid hemor-</span></p>
<p style="top:633.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">rhage</span></p>
<p style="top:633.9pt;left:93.1pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(CONSCIOUS-1):</span></p>
<p style="top:633.9pt;left:173.4pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">randomized,</span></p>
<p style="top:633.9pt;left:235.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">double-blind,</span></p>
<p style="top:643.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">placebo-controlled phase 2 dose-finding trial.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Stroke</span></p>
<p style="top:653.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">39:3015&#x2013;21</span></p>
<p style="top:663.8pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Marbacher S, Neuschmelting V, Graupner T, Jakob SM,</span></p>
<p style="top:673.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Fandino J (2008) Prevention of delayed cerebral vasos-</span></p>
<p style="top:683.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">pasm by continuous intrathecal infusion of glyceroltri-</span></p>
<p style="top:693.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">nitrate and nimodipine in the rabbit model</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> in vivo</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">.</span></p>
<p style="top:703.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Intensive Care Med</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 34:932&#x2013;8</span></p>
<p style="top:713.6pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Matsui T, Asano T (1994) Effects of new 21-aminosteroid</span></p>
<p style="top:723.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">tirilazad mesylate (U74006F) on chronic cerebral vasos-</span></p>
<p style="top:66.1pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">pasm in a</span></p>
<p style="top:64.9pt;left:366.5pt;line-height:6.3pt"><span style="font-family:AdvP4C4E74,serif;font-size:6.3pt">00</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">two-hemorrhage</span><span style="font-family:AdvP4C4E74,serif;font-size:6.3pt">00</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> model of beagle dogs.</span></p>
<p style="top:76.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 34:1035&#x2013;9</span></p>
<p style="top:86.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Matsumura Y, Ikegawa R, Suzuki Y, Takaoka M, Uchida T,</span></p>
<p style="top:96.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Kido H, Shinyama H, Hayashi K, Watanabe M, Mor-</span></p>
<p style="top:105.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">imoto</span></p>
<p style="top:105.9pt;left:345.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">S</span></p>
<p style="top:105.9pt;left:358.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(1991)</span></p>
<p style="top:105.9pt;left:391.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Phosphoramidon</span></p>
<p style="top:105.9pt;left:469.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">prevents</span></p>
<p style="top:105.9pt;left:512.2pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cerebral</span></p>
<p style="top:115.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm following subarachnoid hemorrhage in dogs:</span></p>
<p style="top:125.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">the relationship to endothelin-1 levels in the cerebrosp-</span></p>
<p style="top:135.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">inal fluid.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Life Sci</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 49:841&#x2013;8</span></p>
<p style="top:145.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">McGirt MJ, Lynch JR, Parra A, Sheng H, Pearlstein RD,</span></p>
<p style="top:155.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Laskowitz DT, Pelligrino DA, Warner DS (2002) Simvas-</span></p>
<p style="top:165.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">tatin increases endothelial nitric oxide synthase and</span></p>
<p style="top:175.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">ameliorates cerebral vasospasm resulting from subar-</span></p>
<p style="top:185.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">achnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Stroke</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 33:2950&#x2013;6</span></p>
<p style="top:195.6pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">McGirt MJ, Pradilla G, Legnani FG, Thai QA, Recinos PF,</span></p>
<p style="top:205.5pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Tamargo RJ, Clatterbuck RE (2006) Systemic adminis-</span></p>
<p style="top:215.5pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">tration of simvastatin after the onset of experimental</span></p>
<p style="top:225.4pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid hemorrhage attenuates cerebral vasos-</span></p>
<p style="top:235.4pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">pasm.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 58:945&#x2013;51</span></p>
<p style="top:245.4pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Megyesi JF, Vollrath B, Cook DA, Findlay JM (2000)</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> In vivo</span></p>
<p style="top:255.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">animal models of cerebral vasospasm: a review.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neuro-</span></p>
<p style="top:265.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">surgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 46:448&#x2013;60</span></p>
<p style="top:275.3pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Mesis RG, Wang H, Lombard FW, Yates R, Vitek MP, Borel</span></p>
<p style="top:285.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">CO, Warner DS, Laskowitz DT (2006) Dissociation</span></p>
<p style="top:295.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">between vasospasm and functional improvement in a</span></p>
<p style="top:305.1pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">murine model of subarachnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurg</span></p>
<p style="top:315.1pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Focus</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 21:E4</span></p>
<p style="top:325.1pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Mignini LE, Khan KS (2006) Methodological quality of</span></p>
<p style="top:335.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">systematic reviews of animal studies: a survey of</span></p>
<p style="top:345.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">reviews of basic research.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> BMC Med Res Methodol</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 6:10</span></p>
<p style="top:355.0pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred</span></p>
<p style="top:365.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">reporting items for systematic reviews and meta-ana-</span></p>
<p style="top:374.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">lyses: the PRISMA statement.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> BMJ</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 339:b2535</span></p>
<p style="top:384.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Murphy AM, Xenocostas A, Pakkiri P, Lee TY (2008)</span></p>
<p style="top:394.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Hemodynamic effects of recombinant human erythro-</span></p>
<p style="top:404.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">poietin on the central nervous system after subarach-</span></p>
<p style="top:414.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">noid</span></p>
<p style="top:414.7pt;left:344.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">hemorrhage:</span></p>
<p style="top:414.7pt;left:406.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">reduction</span></p>
<p style="top:414.7pt;left:457.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">of</span></p>
<p style="top:414.7pt;left:476.4pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">microcirculatory</span></p>
<p style="top:424.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">impairment and functional deficits in a rabbit model.</span></p>
<p style="top:434.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">J Neurosurg</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 109:1155&#x2013;64</span></p>
<p style="top:444.6pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK,</span></p>
<p style="top:454.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Rinkel GJ (2009) Changes in case fatality of aneurysmal</span></p>
<p style="top:464.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid haemorrhage over time, according to</span></p>
<p style="top:474.5pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">age, sex, and region: a meta-analysis.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Lancet Neurol</span></p>
<p style="top:484.5pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">8:635&#x2013;42</span></p>
<p style="top:494.4pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Nirei H, Hamada K, Shoubo M, Sogabe K, Notsu Y, Ono T</span></p>
<p style="top:504.4pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(1993)</span></p>
<p style="top:504.4pt;left:350.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">An</span></p>
<p style="top:504.4pt;left:373.3pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">endothelin</span></p>
<p style="top:504.4pt;left:428.3pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">ETA</span></p>
<p style="top:504.4pt;left:456.1pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">receptor</span></p>
<p style="top:504.4pt;left:500.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">antagonist,</span></p>
<p style="top:514.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">FR139317, ameliorates cerebral vasospasm in dogs.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Life</span></p>
<p style="top:524.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Sci</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 52:1869&#x2013;74</span></p>
<p style="top:534.3pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Nosko M, Weir B, Krueger C, Cook D, Norris S, Overton T,</span></p>
<p style="top:544.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Boisvert D (1985) Nimodipine and chronic vasospasm</span></p>
<p style="top:554.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">in monkeys: Part 1. Clinical and radiological findings.</span></p>
<p style="top:564.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 16:129&#x2013;36</span></p>
<p style="top:574.1pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Ohkuma H, Parney I, Megyesi J, Ghahary A, Findlay JM</span></p>
<p style="top:584.1pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(1999) Antisense preproendothelin-oligoDNA therapy</span></p>
<p style="top:594.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">for vasospasm in a canine model of subarachnoid</span></p>
<p style="top:604.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Neurosurg</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 90:1105&#x2013;14</span></p>
<p style="top:614.0pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Pasqualin A, Vollmer DG, Marron JA, Tsukahara T, Kassell</span></p>
<p style="top:623.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">NF, Torner JC (1991) The effect of nicardipine on</span></p>
<p style="top:633.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm in rabbit basilar artery after subarachnoid</span></p>
<p style="top:643.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 29:183&#x2013;8</span></p>
<p style="top:653.9pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P,</span></p>
<p style="top:663.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Clozel JP, Clozel M (1997) Ro 61-1790, a new hydro-</span></p>
<p style="top:673.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">soluble endothelin antagonist: general pharmacology</span></p>
<p style="top:683.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">and</span></p>
<p style="top:683.7pt;left:339.1pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">effects</span></p>
<p style="top:683.7pt;left:374.3pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">on</span></p>
<p style="top:683.7pt;left:393.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">experimental</span></p>
<p style="top:683.7pt;left:456.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cerebral</span></p>
<p style="top:683.7pt;left:498.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm.</span></p>
<p style="top:693.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">J Pharmacol Exp Ther</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 283:1110&#x2013;8</span></p>
<p style="top:703.6pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Santhanam AV, Smith LA, Akiyama M, Rosales AG,</span></p>
<p style="top:713.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Bailey KR, Katusic ZS (2005) Role of endothelial NO</span></p>
<p style="top:723.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">synthase phosphorylation in cerebrovascular protective</span></p>
<p style="top:34.3pt;left:302.9pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicB,serif;font-size:6.9pt">Experimental vasospasm models</span></p>
<p style="top:43.3pt;left:302.9pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicR,serif;font-size:6.9pt">T Zoerle</span><span style="font-family:AdvNewsGothicI,serif;font-size:6.9pt"> et al</span></p>
<p style="top:58.4pt;left:563.2pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1657</span></p>
<p style="top:749.4pt;left:384.2pt;line-height:7.1pt"><span style="font-family:AdvNewsGothicB,serif;font-size:7.1pt">Journal of Cerebral Blood Flow &amp; Metabolism (2012) 32, 1645&#x2013;1658</span></p>


<p style="top:66.1pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">effect of recombinant erythropoietin during subarach-</span></p>
<p style="top:76.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">noid hemorrhage-induced cerebral vasospasm.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Stroke</span></p>
<p style="top:86.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">36:2731&#x2013;7</span></p>
<p style="top:96.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Satoh S, Suzuki Y, Harada T, Ikegaki I, Asano T, Shibuya</span></p>
<p style="top:105.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">M, Sugita K, Hidaka H (1992) Possible prophylactic</span></p>
<p style="top:115.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">potential of HA1077, a Ca2+ channel antagonist and</span></p>
<p style="top:125.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasodilator,</span></p>
<p style="top:125.8pt;left:115.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">on</span></p>
<p style="top:125.8pt;left:133.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">chronic</span></p>
<p style="top:125.8pt;left:172.1pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cerebral</span></p>
<p style="top:125.8pt;left:212.1pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm.</span></p>
<p style="top:125.8pt;left:266.2pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Eur</span></p>
<p style="top:125.8pt;left:287.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">J</span></p>
<p style="top:135.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Pharmacol</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 220:243&#x2013;8</span></p>
<p style="top:145.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Seifert V, Eisert WG, Stolke D, Goetz C (1989) Efficacy of</span></p>
<p style="top:155.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">single intracisternal bolus injection of recombinant</span></p>
<p style="top:165.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">tissue plasminogen activator to prevent delayed cerebral</span></p>
<p style="top:175.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm after experimental subarachnoid hemorrhage</span></p>
<p style="top:185.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">[see comments].</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 25:590&#x2013;8</span></p>
<p style="top:195.6pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Sena ES, van der Worp HB, Bath PM, Howells DW,</span></p>
<p style="top:205.5pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Macleod MR (2010) Publication bias in reports of animal</span></p>
<p style="top:215.5pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">stroke studies leads to major overstatement of efficacy.</span></p>
<p style="top:225.4pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">PLoS Biol</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 8:e1000344</span></p>
<p style="top:235.4pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Shigeno T, Clozel M, Sakai S, Saito A, Goto K (1995) The</span></p>
<p style="top:245.4pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">effect of bosentan, a new potent endothelin receptor</span></p>
<p style="top:255.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">antagonist, on the pathogenesis of cerebral vasospasm.</span></p>
<p style="top:265.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 37:87&#x2013;90</span></p>
<p style="top:275.3pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Steinke DE, Weir BK, Findlay JM, Tanabe T, Grace M,</span></p>
<p style="top:285.2pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Krushelnycky BW (1989) A trial of the 21-aminosteroid</span></p>
<p style="top:295.2pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">U74006F in a</span></p>
<p style="top:295.2pt;left:132.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">primate model of chronic</span></p>
<p style="top:295.2pt;left:258.1pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cerebral</span></p>
<p style="top:305.1pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 24:179&#x2013;86</span></p>
<p style="top:315.1pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Sugawara T, Ayer R, Jadhav V, Chen W, Tsubokawa T,</span></p>
<p style="top:325.1pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Zhang JH (2008) Simvastatin attenuation of cerebral</span></p>
<p style="top:335.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm after subarachnoid hemorrhage in rats via</span></p>
<p style="top:345.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">increased phosphorylation of Akt and endothelial nitric</span></p>
<p style="top:355.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">oxide synthase.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Neurosci Res</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 86:3635&#x2013;43</span></p>
<p style="top:365.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Suzuki H, Kanamaru K, Kuroki M, Sun H, Waga S,</span></p>
<p style="top:374.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Miyazawa T (1998) Effects of unilateral intrathecal</span></p>
<p style="top:384.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">administrations of low dose tissue-type plasminogen</span></p>
<p style="top:394.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">activator on clot lysis, vasospasm and brain phospho-</span></p>
<p style="top:404.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">lipid hydroperoxidation in a primate model of bilateral</span></p>
<p style="top:414.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurol Res</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 20:625&#x2013;31</span></p>
<p style="top:424.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Suzuki H, Kanamaru K, Kuroki M, Sun H, Waga S,</span></p>
<p style="top:434.7pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Miyazawa T (1999) Effects of tirilazad mesylate on</span></p>
<p style="top:444.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm</span></p>
<p style="top:444.6pt;left:112.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">and</span></p>
<p style="top:444.6pt;left:135.3pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">phospholipid</span></p>
<p style="top:444.6pt;left:198.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">hydroperoxides</span></p>
<p style="top:444.6pt;left:270.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">in</span></p>
<p style="top:454.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">primate model of subarachnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Stroke</span><sup><span style="font-family:AdvMelior,serif;font-size:9.0pt">a</span></sup></p>
<p style="top:464.6pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">30:450&#x2013;5</span></p>
<p style="top:474.5pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Takanashi Y, Ishida T, Meguro T, Kirchmeier MJ, Allen TM,</span></p>
<p style="top:484.5pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Zhang JH (2001a) Intrathecal application with liposome-</span></p>
<p style="top:494.4pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">entrapped Fasudil for cerebral vasospasm following</span></p>
<p style="top:504.4pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid hemorrhage in rats.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Clin Neurosci</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 8:</span></p>
<p style="top:514.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">557&#x2013;561</span></p>
<p style="top:524.3pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Takanashi Y, Ishida T, Meguro T, Kiwada H, Zhang JH,</span></p>
<p style="top:534.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Yamamoto I (2001b) Efficacy of intrathecal liposomal</span></p>
<p style="top:544.3pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">fasudil for experimental cerebral vasospasm after sub-</span></p>
<p style="top:554.2pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">arachnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 48:894&#x2013;900</span></p>
<p style="top:564.2pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Takata K, Sheng H, Borel CO, Laskowitz DT, Warner DS,</span></p>
<p style="top:574.1pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Lombard FW (2008) Long-term cognitive dysfunction</span></p>
<p style="top:584.1pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">following experimental subarachnoid hemorrhage: new</span></p>
<p style="top:594.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">perspectives.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Exp Neurol</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 213:336&#x2013;44</span></p>
<p style="top:604.0pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Tang WH, Chen Z, Liu Z, Zhang JH, Xi G, Feng H (2008)</span></p>
<p style="top:614.0pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">The</span></p>
<p style="top:614.0pt;left:84.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">effect</span></p>
<p style="top:614.0pt;left:114.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">of</span></p>
<p style="top:614.0pt;left:130.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">ecdysterone</span></p>
<p style="top:614.0pt;left:187.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">on</span></p>
<p style="top:614.0pt;left:206.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cerebral</span></p>
<p style="top:614.0pt;left:246.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm</span></p>
<p style="top:623.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">following experimental subarachnoid hemorrhage</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> in</span></p>
<p style="top:633.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vitro</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> and</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> in vivo</span><span style="font-family:AdvMelior,serif;font-size:9.0pt">.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurol Res</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 30:571&#x2013;80</span></p>
<p style="top:643.9pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Titova E, Ostrowski RP, Zhang JH, Tang J (2009) Experi-</span></p>
<p style="top:653.9pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">mental models of subarachnoid hemorrhage for studies</span></p>
<p style="top:663.8pt;left:60.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">of cerebral vasospasm.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurol Res</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 31:568&#x2013;81</span></p>
<p style="top:66.1pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Turowski B, Hanggi D, Beck A, Aurich V, Steiger HJ,</span></p>
<p style="top:76.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Moedder U (2007) New angiographic measurement tool</span></p>
<p style="top:86.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">for analysis of small cerebral vessels: application to a</span></p>
<p style="top:95.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid haemorrhage model in the rat.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neuror-</span></p>
<p style="top:105.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">adiology</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 49:129&#x2013;37</span></p>
<p style="top:115.8pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell</span></p>
<p style="top:125.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">S, O&#x2019;Collins V, Macleod MR (2010) Can animal models</span></p>
<p style="top:135.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">of disease reliably inform human studies?</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> PLoS Med</span></p>
<p style="top:145.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">7:e1000245</span></p>
<p style="top:155.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Vergouwen MD, Vermeulen M, Coert BA, Stroes ES,</span></p>
<p style="top:165.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Roos YB (2008) Microthrombosis</span></p>
<p style="top:165.7pt;left:471.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">after aneurysmal</span></p>
<p style="top:175.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid hemorrhage: an additional explanation</span></p>
<p style="top:185.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">for delayed cerebral ischemia.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Cereb Blood Flow Metab</span></p>
<p style="top:195.5pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">28:1761&#x2013;70</span></p>
<p style="top:205.5pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Vollmer DG, Kassell NF, Hongo K, Ogawa H, Tsukahara T</span></p>
<p style="top:215.5pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(1989) Effect of the nonglucocorticoid 21-aminosteroid</span></p>
<p style="top:225.4pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">U74006F experimental cerebral vasospasm.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Surg Neurol</span></p>
<p style="top:235.4pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">31:190&#x2013;4</span></p>
<p style="top:245.4pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Wanebo JE, Arthur AS, Louis HG, West K, Kassell NF, Lee</span></p>
<p style="top:255.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">KS, Helm GA (1998) Systemic administration of the</span></p>
<p style="top:265.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">endothelin-A receptor antagonist TBC 11251 attenuates</span></p>
<p style="top:275.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cerebral vasospasm after experimental subarachnoid</span></p>
<p style="top:285.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">hemorrhage: dose study and review of endothelin-based</span></p>
<p style="top:295.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">therapies</span></p>
<p style="top:295.2pt;left:359.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">in the literature on cerebral vasospasm.</span></p>
<p style="top:305.1pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 43:1409&#x2013;17</span></p>
<p style="top:315.1pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Wanebo JE, Louis HG, Arthur AS, Zhou J, Kassell NF,</span></p>
<p style="top:325.1pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Lee KS, Helm GA (1997) Attenuation of cerebral</span></p>
<p style="top:335.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm by systemic administration of an endo-</span></p>
<p style="top:345.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">thelin-A receptor antagonist, TBC 11251, in a rabbit</span></p>
<p style="top:355.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">model of subarachnoid hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurg Focus</span></p>
<p style="top:365.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">3: E8</span></p>
<p style="top:374.9pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Wang Z, Chen G, Zhu WW, Bian JY, Shen XO, Zhou D</span></p>
<p style="top:384.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(2010) Influence of simvastatin on microthrombosis in</span></p>
<p style="top:394.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">the brain after subarachnoid hemorrhage in rats: a</span></p>
<p style="top:404.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">preliminary study.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Ann Clin Lab Sci</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 40:32&#x2013;42</span></p>
<p style="top:414.7pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Willette RN, Zhang H, Mitchell MP, Sauermelch CF,</span></p>
<p style="top:424.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Ohlstein EH, Sulpizio AC (1994) Nonpeptide endothe-</span></p>
<p style="top:434.7pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">lin antagonist. Cerebrovascular characterization and</span></p>
<p style="top:444.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">effects</span></p>
<p style="top:444.6pt;left:352.2pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">on</span></p>
<p style="top:444.6pt;left:373.7pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">delayed</span></p>
<p style="top:444.6pt;left:417.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cerebral</span></p>
<p style="top:444.6pt;left:460.7pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm.</span></p>
<p style="top:444.6pt;left:518.6pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Stroke</span></p>
<p style="top:454.6pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">25:2450&#x2013;5</span></p>
<p style="top:464.6pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Zabramski J, Spetzler RF, Bonstelle C (1986) Chronic</span></p>
<p style="top:474.5pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">cerebral</span></p>
<p style="top:474.5pt;left:355.2pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">vasospasm:</span></p>
<p style="top:474.5pt;left:409.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">effect</span></p>
<p style="top:474.5pt;left:439.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">of</span></p>
<p style="top:474.5pt;left:455.5pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">calcium</span></p>
<p style="top:474.5pt;left:496.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">antagonists.</span></p>
<p style="top:484.5pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 18:129&#x2013;35</span></p>
<p style="top:494.4pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Zimmermann M, Seifert V, Loffler BM, Stolke D, Stenzel W</span></p>
<p style="top:504.4pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(1996) Prevention of cerebral vasospasm after experi-</span></p>
<p style="top:514.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">mental subarachnoid hemorrhage by RO 47-0203, a</span></p>
<p style="top:524.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">newly developed orally active endothelin receptor</span></p>
<p style="top:534.3pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">antagonist.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> Neurosurgery</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 38:115&#x2013;20</span></p>
<p style="top:544.3pt;left:302.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Zuccarello M, Boccaletti R, Romano A, Rapoport RM</span></p>
<p style="top:554.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">(1998) Endothelin B receptor antagonists attenuate</span></p>
<p style="top:564.2pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">subarachnoid hemorrhage-induced cerebral vasospasm.</span></p>
<p style="top:574.1pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Stroke</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 29:1924&#x2013;9</span></p>
<p style="top:584.1pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Zuccarello</span></p>
<p style="top:584.1pt;left:354.4pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">M,</span></p>
<p style="top:584.1pt;left:373.2pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Marsch</span></p>
<p style="top:584.1pt;left:411.4pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">JT,</span></p>
<p style="top:584.1pt;left:430.0pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Schmitt</span></p>
<p style="top:584.1pt;left:470.1pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">G,</span></p>
<p style="top:584.1pt;left:486.9pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Woodward</span></p>
<p style="top:594.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Anderson DK (1989) Effect of the 21-aminosteroid U-</span><sup><span style="font-family:AdvMelior,serif;font-size:9.0pt">J,</span></sup></p>
<p style="top:604.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">74006F on cerebral vasospasm following subarachnoid</span></p>
<p style="top:614.0pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">hemorrhage.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Neurosurg</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> 71:98&#x2013;104</span></p>
<p style="top:623.9pt;left:302.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Zuccarello M, Soattin GB, Lewis AI, Breu V, Hallak H,</span></p>
<p style="top:633.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Rapoport RM (1996) Prevention of subarachnoid hemor-</span></p>
<p style="top:643.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">rhage-induced cerebral vasospasm by oral administra-</span></p>
<p style="top:653.9pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">tion of endothelin receptor antagonists.</span><span style="font-family:AdvMelior,serif;font-size:9.0pt"> J Neurosurg</span></p>
<p style="top:663.8pt;left:314.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">84:503&#x2013;7</span></p>
<p style="top:683.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">Supplementary Information accompanies the paper on the Journal of Cerebral Blood Flow &amp; Metabolism website (http://</span></p>
<p style="top:693.7pt;left:48.8pt;line-height:9.0pt"><span style="font-family:AdvMelior,serif;font-size:9.0pt">www.nature.com/jcbfm)</span></p>
<p style="top:34.3pt;left:206.8pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicB,serif;font-size:6.9pt">Experimental vasospasm models</span></p>
<p style="top:43.3pt;left:256.6pt;line-height:6.9pt"><span style="font-family:AdvNewsGothicR,serif;font-size:6.9pt">T Zoerle</span><span style="font-family:AdvNewsGothicI,serif;font-size:6.9pt"> et al</span></p>
<p style="top:58.4pt;left:12.9pt;line-height:8.0pt"><span style="font-family:AdvMelior,serif;font-size:8.0pt">1658</span></p>
<p style="top:749.4pt;left:12.9pt;line-height:7.1pt"><span style="font-family:AdvNewsGothicB,serif;font-size:7.1pt">Journal of Cerebral Blood Flow &amp; Metabolism (2012) 32, 1645&#x2013;1658</span></p>

</div>
